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ABSTRACT 
 
Histone deacetylases (HDACs) are enzymes involved in the remodeling of 
chromatin. In recent years, inhibition of HDACs has emerged as a potential 
strategy to reverse aberrant epigenetic changes associated with cancer. In fact, 
HDAC inhibitors (HDACi) promote apoptosis, induce cell cycle arrest and 
differentiation of tumor cells, by mechanisms which remain in part unknown. T-
cell acute lymphoblastic leukemia (T-ALL) is a pediatric malignancy 
characterized by clonal expansion of lymphoid progenitors. Although the majority 
of pediatric T-ALL patients can be cured by current protocols, about one fourth of 
patients has chemotherapy-resistant disease or relapse after therapy and novel 
therapeutic approaches are required. In our study, we analyzed the effects of 
HDACi on seven transcription factors important in T-ALL pathogenesis 
(NOTCH1, NOTCH3, c-MYB, TAL1, TLX1, TLX3 and LMO2) using both 
established T-ALL cell lines and patient-derived T-ALL xenografts previously 
obtained in our laboratory. In particular, we focused on transcription factors that 
define specific T-ALL  subgroups (TAL/LMO, TLX1, TLX3) and we included 
members of the Notch family (NOTCH1 and NOTCH3) and c-MYB in view of 
their transversal role in T-ALL. In vitro analysis highlighted transcriptional down-
regulation of C-MYB and TAL1, a post-translation regulation of NOTCH1 and 
NOTCH3 and the regulation of the transcriptional activity of TLX1 and TLX3 
following HDAC inhibition. These biochemical effects were linked to increased 
apoptosis and impaired proliferation both in T-ALL cell lines and patients-derived 
cells, partially dependent on NOTCH1  and NOTCH3. We next investigated the in 
vivo effects of the HDACi Givinostat in T-ALL xenografts belonging to specific 
T-ALL subgroups. Interestingly, PD-TALL8 (TLX1) and PD-TALL16 (TLX3) 
had better response to treatment compared to PD-TALL12 and PD-TALL9 
(TAL/LMO). In fact, Givinostat dramatically decreased leukemic cells infiltrating 
the spleen and the bone marrow in TLX-driven xenografts, whereas this drug had 
modest or minimal effects on TAL/LMO xenografts. Taken together, these results 
identify TLX1 and TLX3 T-ALL subgroups as potential candidates for 
therapeutic treatment with HDACi such as Givinostat. 
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RIASSUNTO 
 
Le Istone Deacetilasi (HDACs) sono enzimi coinvolti nel rimodellamento della 
cromatina. Negli ultimi anni è emerso come l’inibizione delle HDACs potrebbe 
essere utilizzata come strategia per ripristinare l’alterata regolazione epigenetica 
che si riscontra nei tumori. Infatti, gli inibitori delle HDAC (HDACi) inducono 
apoptosi, arresto del ciclo cellulare e differenziamento delle cellule tumorali, ma i 
meccanismi molecolari alla base di questi fenomeni rimangono poco chiari. La 
leucemia linfoblastica acuta a cellule T (T-ALL) è un tumore pediatrico 
caratterizzato dall’espansione clonale di progenitori linfoidi. Nonostante la 
maggioranza dei pazienti pediatrici affetti da T-ALL siano curati in modo efficace 
utilizzando gli attuali protocolli terapeutici, circa un quarto dei pazienti manifesta 
resistenza alla terapia o presenta ricadute e dunque emerge la necessità di nuovi 
approcci terapeutici. In questo studio abbiamo analizzato gli effetti degli HDACi 
nei confronti di sette fattori di trascrizione implicati nella patogenesi della T-ALL 
(NOTCH1, NOTCH3, c-MYB, TAL1, TLX1, TLX3 and LMO2) utilizzando sia 
linee cellulari stabilizzate, sia modelli murini di T-ALL precedentemente 
sviluppati nel nostro laboratorio a partire da cellule di pazienti. In particolare, ci 
siamo concentrati su fattori trascrizionali che identificano specifici sottogruppi di 
T-ALL (TAL/LMO, TLX1 e TLX3) e abbiamo incluso nell’analisi due membri 
della famiglia dei recettori Notch (NOTCH1 and NOTCH3) e c-MYB  in virtù del 
loro ruolo oncogenico in questa patologia. Le analisi in vitro hanno evidenziato 
diversi meccanismi di regolazione dei vari fattori da parte degli HDACi. TAL1 e 
c-MYB risultano regolati a livello trascrizionale, NOTCH1 e NOTCH3 
presentano una regolazione post-traduzionale e, nel caso di TLX 1 e TLX3, è 
presente una regolazione diretta della loro capacità trascrizionale. Gli effetti a 
livello di proteina si legano all’induzione di apoptosi e all’inibizione della 
proliferazione sia nelle linee cellulari, sia nelle cellule derivate da paziente e 
risultano essere parzialmente dovute alla down-modulazione di NOTCH1 e 
NOTCH3. In seguito siamo andati ad indagare la risposta in vivo dell’HDACi 
Givinostat in xenografts di T-ALL appartenenti a specifici sottogruppi genetici. E’ 
interessante notare che il trattamento ha avuto il maggiore risultato nelle PD-
TALL8 (TLX1) e nelle PD-TALL16 (TLX3) rispetto alle PD-TALL12 e le PD-
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TALL9 (entrambe TAL/LMO). Infatti, il trattamento con Givinostat negli 
xenografts di tipo TLX determina una riduzione dell’infiltrazione da parte delle 
cellule leucemiche nella milza e nel midollo mentre gli effetti ottenuti negli 
xenografts TAL/LMO risultano modesti o addirittura nulli. In conclusione, i dati 
ottenuti identificano i pazienti di T-ALL appartenenti ai sottogruppi TLX1 e 
TLX3 come potenziali candidati per il trattamento a scopo terapeutico con 
HDACi come il Givivnostat.  
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1. INTRODUCTION 
 
1.1 T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA 
1.1.1 Pathogenesis 
 
T-cell acute lymphoblastic leukaemia (T-ALL) is a neoplastic disorder of the 
lymphoblast committed to the T-cell lineage. T-ALL represents 15% of childhood 
and 25% of adult ALL and is characterized by an unfavourable prognosis 
compared to B cell ALL. Patients present high levels of circulating blasts, 
infiltration of bone marrow and spleen and, in some cases, involvement of central 
nervous system (Graux et al., 2006). T-ALL is thought to result from malignant 
thymocytes that arise at defined stages of intrathymic T-cell differentiation. 
Transformation events occur in crucial steps of thymocyte development and 
determine an arrest at particular stages of normal thymocyte development 
(Aifantis et al., 2008). Sequential alterations in proto-oncogenes, tumour-
suppressor genes, and microRNA genes could involve hematopoietic stem cells or 
their committed progenitors. These fundamental changes alter key regulatory 
processes in target cells by conferring an unlimited capacity for self-renewal, 
altering the controls of normal proliferation, blocking cell differentiation, and 
promoting resistance to death signals (Pui, 2009). 
Cytogenetic analysis of lymphoblasts reveals recurrent translocations that activate 
a small number of oncogenes in 25–50% of T-ALL but a large proportion of T-
ALL shows a normal karyotype. The abnormal karyotypes found in 
approximately 50% of T-ALL cases (Table 1), however, are still less than the 
percentage found in B-cell-lineage ALL cases (Aifantis et al., 2008). 
 
Table 1: Common cytogenetic abnormalities in T-ALL (Aifantis et al., 2008). 
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The most frequent genetic abnormalities can be divided in: 
 
• Translocations involving the T cell receptor (TCR). About 40% of T-ALL        
harbour chromosomal translocations juxtaposing a transcription factor, 
important in thymocytes development, next to strong regulatory elements 
(promoter and enhancer) located near to the T-cell receptor β (TCRB) 
gene on chromosome 7 or the T-cell receptor α-δ (TCRAD) locus on 
chromosome 14. These chromosomal translocations can occur during 
thymocyte development as results of uncorrected TCR recombination and 
lead to aberrant gene expression giving rise to T cells that show abnormal 
cell cycle control, proliferation and differentiation. The most frequent 
translocations involve HOX genes (including HOX11, HOX11L2, also 
known as TLX1 and TLX3 and HOXA) or genes coding for proteins 
interacting with E2A (TAL1, TAL2, LYL1, BHLHB1, LMO1 and LMO2) 
(Tosello and Ferrando, 2013). 
• Formation of chimeric protein with oncogenic properties. Additional 
genetic abnormalities in T cells from patients with T-ALL include 
chromosomal translocations that generate fusion genes encoding new 
chimeric proteins with oncogenic properties, such as the SIL-TAL1 fusion 
protein and fusion proteins that involve MLL, ABL1 and NUP98. 
• Tumour suppressor deletions. The most common cryptic deletions in T-
ALL, leading to the loss of tumour suppressors, are deletions of the INK4 
(also known as CDKN2A) locus at chromosome 9p21, which contains 
genes encoding the cyclin-dependent kinase inhibitor p16 and other 
proteins important in regulation of the cell cycle (Aifantis et al., 2008). 
• Activating mutations. Recently, it has also been found that more than 50% 
of T-ALL cases has activating mutations in the key regulator of T-cell fate 
NOTCH1 (Weng et al., 2004). These activating mutations lead to high 
levels of NOTCH1 signalling and give a proliferation advantage to the 
cell, mainly due to secondary effects on key regulators of cell cycle and 
apoptosis (Palomero et al., 2006). Moreover, 15% of T-ALL patients 
harbour mutations or deletions in the ubiquitin-ligase  FBW7, responsible 
for NOTCH1 ICD degradation, mimicking the effects of Notch1 mutations 
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(O'Neil et al., 2004). Other oncogenes that can present activating 
mutations are NRAS and FLT3. 
• Duplications. Recent studies have explored the importance of the 
transcription factor c-MYB in T-ALL. In particular, a duplication of the 
transcription factor c-MYB was identified in about 8% of T-ALL patients 
(Clappier et al., 2007; Lahortiga et al., 2007) and in about 30% of T-ALL 
cell lines (Aifantis et al., 2008). 
 
Moreover, altered expression or ectopic activation of transcription factors in T-
ALL are reported, without evident cytogenetic alterations. Regarding this, it was 
previously reported that also enforced expression of Notch3-ICD is a potent 
inducer of T cell leukaemia in mouse model and that Notch3 over-expression 
characterizes human T-ALL, even if mutations in this Notch paralog have not 
been reported (Bellavia et al., 2000; Screpanti et al., 2003).  
 
1.1.2 Gene expression signatures identify different T-ALL 
subgroups 
 
Careful analysis of clonal chromosomal abnormalities in leukemic blast cells had 
a greater impact on the B lineage leukaemias than on T cell acute lymphoblastic 
leukaemia (T-ALL), whose pathogenesis and molecular subtypes remained, for 
long time, largely undefined. In fact, the different clinical outcome of T-ALL 
patients reflects a molecular heterogeneity that cannot be appreciated using 
conventional cytogenetic analysis. Gene expression analysis using oligonucleotide 
or cDNA microarrays have been used by several groups as a novel tool for 
delineating molecular pathways that drive the malignant transformation of 
developing thymocytes (Ferrando et al., 2002; Ross et al., 2003; Soulier et al., 
2005; Yeoh et al., 2002). Some genetic abnormalities occur in a mutually 
exclusive manner and have been defined as type A mutations. Type A mutations 
involved driving oncogenes and, based on gene expression profiling, define four 
main distinct genetic T-ALL subgroups: TAL1/LMO, TLX1, TLX3 and HOXA 
(Table 2).  
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Table 2: Genetic subgroups in paediatric T-cell acute lymphoblastic leukaemia (Meijerink, 
2010).  
 
The TLX3 and TLX1 subgroups are exclusively characterized by rearrangements 
of the TLX3 and TLX1 oncogenes respectively. TLX1 and TLX3 are over-
expressed in 10% and 30% of paediatric T-ALL, respectively, as a consequence of 
chromosomal translocations. Genes bound by these homeobox transcription 
factors are characteristically down-regulated, suggesting that TLX1 and TLX3 
primarily function as transcriptional repressors. In particular, in neural stem cells 
it has been demonstrated that TLX1 and TLX3 recruit histone deacetylases 
(HDACs) and form a silencing complex on target genes promoter (Sun et al., 
2007). TLX1 and TLX3 are implied in T-cell maturation and, in particular, they 
act as antagonists of physiological thymocyte differentiation. In this regard,  
TLX1/3 silencing in human T-ALL cell lines increases differentiation and cell 
death, suggesting a differentiation arrest and induction of apoptosis. Moreover, T-
ALL patients harbouring TLX1/3 signature are characterized by early cortical 
thymocytes, confirming their effect on T-cell differentiation (Dadi et al., 2012). In 
contrast to TLX1/3 subgroups, the TAL/LMO and HOXA subgroups seem to be 
characterized by the presence of various rearrangements affecting several, but 
functionally equivalent oncogenes. TAL1 and LMO2 normally participate in the 
same transcriptional complex that regulates the activity of the important 
E2A/HEB transcription factors (O'Neil et al., 2004). This may explain why TAL1 
or LMO2-rearranged T-ALL cases have highly similar if not identical gene 
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expression profiles. Mutations that are found in more than one genetic subgroup 
are the so-called type B mutations (Table 3). These mutations affect various 
cellular processes, and include loss of cell cycle inhibitors p15 and p16, activation 
of the NOTCH1 pathway, activating mutations in the RAS pathway, mutations 
resulting in the activation of the AKT pathway, or chromosomal rearrangements 
that result in fusion proteins with tyrosine kinase activity (Meijerink, 2010). 
 
 
Table 3: Classification of common abnormalities in T-cell acute lymphoblastic leukaemia 
(Meijerink, 2010).  
 
 
Common aberrations found in T-ALL are NOTCH1 activating mutations that 
occur in over 60% of the T-ALL leukaemias. These mutations involve activating 
mutations in NOTCH1 itself or inactivating mutations in the E3-ubiquitin ligase 
gene FBXW7. These mutations are found in all genetic subgroups, although the 
incidence of NOTCH1 activating mutations is relatively higher for TLX3-
rearranged cases, but lower within the TAL/LMO subgroup. NOTCH1 mutations 
affecting the heterodimerization domain (HD) result in a ligand-independent 
release of the intracellular domain of NOTCH1 (ICD), which subsequently 
translocates into the nucleus where it acts as a transcription factor. Alternatively, 
NOTCH1 PEST domain mutations or inactivating FBXW7 mutations preserve 
ICD from ubiquitin-mediated degradation in the proteasome. Interestingly, 
although Notch1 is a potent inducer of T-leukaemia and activating mutations are 
founded in a high percentage of T-ALL patients, this oncogene does not identify a 
specific subgroup.  
 
 
 
  
10 
1.1.3 Treatment of ALL 
  
Current therapies for ALL can cure more than 80% of children and fewer than 
50% of adults with this haematological malignancy. For this reason new 
therapeutic approaches are required (Pui and Evans, 2006). Children with ALL 
are usually treated according to risk groups defined by both clinical and laboratory 
features. The intensity of treatment to achieve favourable outcome varies 
substantially according to patients stratification. Risk-based treatment assignment 
is utilized in children with ALL in order to spare unnecessary intensive and toxic 
treatment. Therapy of T-ALL is generally divided into three phases: (I) 
remission/induction therapy followed by (II) consolidation/intensification therapy 
and, finally, (III) maintenance/continuation treatment. Certain ALL study groups, 
such as the Children’s Oncology Group (COG), use a more or less intensive 
induction regimen based on pre-treatment factors, while other groups give a 
similar induction regimen to all patients. Factors used by the COG to determine 
the intensity of induction include immunophenotype and the National Cancer 
Institute (NCI) risk group classification. The NCI risk group classification 
stratifies risk according to age and white blood cell (WBC) count: 
 
• Standard risk - WBC count less than 50,000/µL and age 1 to younger 
than 10 years. 
• High risk - WBC count 50,000/µL or greater and/or age 10 years or 
older. 
 
In addition to this classification, ALL patients can be stratified according to other 
prognostic factors: 
• Patients characteristics. Central Nervous System (CNS) and testicular 
involvement at diagnosis are adverse prognostic factors. Regarding gender, the 
prognosis for girls with ALL is slightly better than it is for boys with ALL. This 
could be explain by the occurrence of testicular relapses among boys, but boys 
also appear to be at increased risk of bone marrow and CNS relapse for reasons 
that are not well understood. Down Syndrome and race are also considered 
prognostic factors in induction treatment. 
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• Leukemic cells characteristics. Leukemic cell characteristics affecting 
prognosis include morphology, immunophenotype (B-ALL or T-ALL) and 
cytogenetic/genomic alterations. Recurrent chromosomal abnormalities have 
been shown to have prognostic significance, especially in B-precursor ALL. 
• Response to initial treatment. Long-term outcome is associated with 
elimination of leukemic cells after initial treatment and the level of residual 
disease at the end of induction phase. Treatment response is influenced by the 
drug sensitivity of leukemic cells and host pharmacodynamics and 
pharmacogenomics. For this reason, early response has strong prognostic 
significance. Leukaemia response is evaluated by minimal residual disease 
(MRD) parameters that allow to monitored leukemic cells in the bone marrow 
using molecular features that are not expressed by normal lympho-hematopoietic 
cells (clonal rearrangement of immunoglobulin (IG) and T-cell               receptor 
(TCR) genes and chromosomal abnormalities by PCR, cell marker profiles by 
flow cytometric analysis). (Campana and Coustan-Smith, 2012) and 
http://www.cancer.gov/cancertopics/pdq/treatment/adultALL/HealthProfessional, National 
Cancer Institute web site). 
Standard remission-induction therapy for newly diagnosed childhood ALL 
include a multidrug chemotherapy with vincristine, corticosteroid (prednisone or 
dexamethasone), L-asparaginase and an anthracycline (doxorubicin or 
daunorubicin). Glucocorticoids were among the first drugs used in the treatment 
of ALL and have remained essential components of therapy. Their cytotoxic 
effect seems to be mediated through binding of glucocorticoid receptors and 
consequent inhibition of cytokine production, alteration of the expression of 
various oncogenes, and induction of cell cycle arrest and apoptosis. 
Glucocorticoid resistance is an adverse prognostic factor in ALL, and several 
mechanisms have been reported (Inaba and Pui, 2010). The goal of remission-
induction therapy is to eradicate more than 99% of the initial burden of 
leukaemia cells and to restore normal haematopoiesis (Pui and Evans, 2006). The 
vast majority of children with ALL achieve complete morphologic remission by 
the end of the first month of treatment. However, the presence of more than 5% 
lymphoblasts at the end of the induction phase is observed in up to 5% of 
children with ALL. Once complete remission (CR) has been achieved, systemic 
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treatment in conjunction with CNS-directed therapy follows. Standard treatment 
options for CNS-directed therapy include intratecal chemotherapy (usually 
methotrexate), CNS-directed Systemic Chemotherapy and, in some cases, cranial 
radiation. The intensity of the post-induction chemotherapy varies considerably 
depending on risk group assignment, but all patients receive some form of 
intensification after the achievement of CR and before beginning maintenance 
therapy. Commonly used regimens for child-hood ALL include high-dose 
methotrexate with mercaptopurine, high-dose asparaginase given for an extended 
period, and reinduction treatment. Finally, patients are subjected to 
maintenance/continuation treatment in order to eliminate residual leukaemia 
cells. Patients with ALL require prolonged continuation therapy, at least two 
years, and attempts to shorten this phase have yielded poor results in both 
children and adults. The maintenance/continuation therapy is based on the 
combination of methotrexate and mercaptopurine administrated weekly and daily 
respectively, with or without pulses of dexamethasone and vincristine (Pui and 
Evans, 2006).  
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1.2 HISTONE DEACETYLASES (HDACs)  
1.2.1 HDACs family: structure and functions 
 
Transcription in eukaryotic cells is influenced by DNA organization in the 
nucleus. In fact, DNA is packaged into chromatin, a highly organized and 
dynamic protein-DNA complex. The core subunit of chromatin is the nucleosome, 
composed of an octamer of four core histones, an H3/H4 tetramer and two 
H2A/H2B dimers, surrounded by 146 bp of DNA. Local chromatin organization 
is generally recognized as an important factor in the regulation of gene 
expression. During activation of gene transcription, the inaccessible structure of 
DNA become available to DNA binding proteins through modification of the 
nucleosomes. Remodelling of chromatin is strongly influenced by post-
translational modifications of the histones, such as  acetylation, methylation, 
phosphorylation, poly-ADP ribosylation, ubiquitinylation, sumoylation, 
carbonylation and glycosylation. Compared with other modifications, acetylation 
of core histones is probably the best understood type of epigenetic modification. 
The balance between “open” and “close” chromatin forms is driven by two classes 
of enzyme with different activities: histone acetyltransferases (HATs) transfer 
acetyl groups to amino-terminal lysine residues of histones, which results in local 
expansion of chromatin and increased accessibility of regulatory proteins to DNA, 
whereas histone deacetylases (HDACs) catalyze the removal of acetyl groups, 
leading to chromatin condensation and transcriptional repression (Fig.1) (de 
Ruijter et al., 2003).  
 
                    
Fig.1: HDACs and HATs opposite activities on chromatin condensation in the nucleus. 
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Eighteen HDACs have been identified in humans, and they are subdivided into 
two protein families: the Zn2+ dependent classical HDAC family (class I, II and 
IV), and the Zn2+-independent NAD+-dependent Sirtuins (class III). The classical 
HDAC family consists of four classes based on their homology to yeast HDACs, 
their subcellular localization and their enzymatic activities. The class I HDACs (1, 
2, 3 and 8) are homologous to the yeast RPD3 protein, can generally be localized 
in the nucleus and are ubiquitously expressed in various human cell lines and 
tissues. Class II HDACs (4, 5 ,6, 7, 9 and 10) share homologies with the yeast 
Hda1 protein and can shuttle between the nucleus and the cytoplasm. This 
subgroup is further divide in class IIa (4, 5, 7 and 9) and class IIb (6 and 10). In 
particular, HDACs 6 and 10 are found in the cytoplasm and contain two 
deacetylase domains. HDAC6 has unique substrate specificity with an α-tubulin 
deacetylase (TDAC) domain specific for the cytoskeletal protein α-tubulin. 
HDAC11 is the only member of the class IV HDACs. It shares sequence 
similarity with the catalytic core regions of both class I and II enzymes but does 
not have strong enough identity to be placed in either class. The class III HDACs 
(SIRT1, 2, 3, 4, 5, 6 and 7) are homologues of the yeast protein Sir2 and require 
NAD+ for their activity to regulate gene expression in response to changes in the 
cellular redox status. (Table 4)(Bolden et al., 2006; Thiagalingam et al., 2003). 
 
 
Table 4: The classification of HDACs in mammals (Pan et al., 2007). 
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1.2.2 Non-histone proteins as substrates of HDACs 
 
Interestingly, despite the importance of HDACs in the regulation of genes 
expression, genome-wide transcript profiling by microarrays has indicated that a 
relatively small percentage of genes (between 2% and 5%) is influenced by 
HDAC inhibition (Glaser et al., 2003; Johnstone and Licht, 2003). To this end, 
recent studies focused their attention on HDACs target alternative to histones. 
Recent phylogenetic analyses of bacterial HDACs suggest that all four HDAC 
classes preceded the evolution of histone proteins (Gregoretti et al., 2004). This 
suggests that the primary activity of HDACs may be directed against non-histone 
substrates. At least 50 non-histone proteins of known biological function have 
been identified, which may be acetylated and substrates of HDACs. Non-histone 
protein targets of HDACs include transcription factors, transcription regulators, 
signal transduction mediators, DNA repair enzymes, nuclear import regulators, 
chaperone proteins, structural proteins, inflammation mediators and viral proteins 
(Table 5) (Xu et al., 2007). 
 
                     
Table 5: Non-histone substrates of HDACs (Xu et al., 2007). 
 
 
Unlike other histone deacetylases with chromatin remodelling activity, HDAC6 
catalyzes deacetylation of cytoplasmic substrates, such as α-tubulin, Hsp90, and 
cortactin. In particular, it has been demonstrated that HDAC6 inhibition 
determines increased acetylation of α-tubulin (Zhang et al., 2003) and, 
consequently, promotes the association of microtubules with dynein and kinesin 
motors, leading to increased motor processivity and secretory vesicle flux. These 
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results show a potentially regulatory role for HDAC6 in endocytic cargo transport 
(Gao et al., 2010; Reed et al., 2006). Moreover, this HDAC is implied in the 
aggresome formation, an aggregate of ubiquitinated misfolded proteins, 
commonly found in neurodegenerative pathologies and tumour cells (Boyault et 
al., 2007; Rodriguez-Gonzalez et al., 2008).  
 
 
1.2.3 HDACs as targets in cancer treatment 
 
The fact that acetylation is a key component in the regulation of gene expression 
has stimulated the study of HDACs in relation to the aberrant gene expression 
often observed in cancer. Cancer has traditionally been considered a disease 
caused by genetic alterations such as gene mutations, deletions and chromosomal 
abnormalities, that result in the loss of function of tumour-suppressor genes and/or 
gain of function or hyper-activation of oncogenes. However, there is growing 
evidence that gene expression regulated by epigenetic changes is also important 
for the progression of cancer. Recent studies have focused the attention on the 
aberrant recruitment of HDACs by oncogenic DNA-binding proteins, resulting 
from chromosomal translocations. For example, the oncogenic PML–RARα, 
PLZF–RARα and AML1–ETO fusion proteins induce acute promyelocytic 
leukaemia(APL) and acute myeloid leukaemia (AML) by recruiting HDAC-
containing complexes that constitutively repress the expression of specific target 
genes (Lin et al., 2001). In addition to aberrant recruitment of HDACs to specific 
loci, altered expression of individual HDACs in tumours has also been reported. 
HDAC1 is over-expressed in prostate (Halkidou et al., 2004), gastric (Choi et al., 
2001), colon, breast carcinomas (Zhang et al., 2005). HDAC2 showed higher 
expression in colorectal (Zhu et al., 2004), cervical and gastric cancer (Song et al., 
2005). Increased expression of HDAC3 is seen in colon tumours (Wilson et al., 
2006). HDAC6 over-expression is observed in breast cancer (Zhang et al., 2004). 
Concerning haematological tumours, few works examined the differentially 
expressed HDACs in ALL patients. In 2010  Moreno and colleagues (Moreno et 
al., 2010) identified  HDAC3, HDAC7 and HDAC9 as the most over-expressed 
HDACs in ALL patients and their altered expression was associated with poor 
prognosis in childhood ALL. Similar results were obtained by Gruhn et al. in 
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2013 (Gruhn et al., 2013). In addition to the previous work, a correlation analysis 
of HDAC expression with clinico-pathological parameters revealed that high 
HDAC4 expression was associated with prednisone poor-response in T-ALL 
patients. Moreover, siRNA-mediated inhibition of HDAC4 sensitized a T-ALL 
cell line to etoposide induced cell death. 
At present, the relationships between aberrant expression of various HDACs and 
cancer remain unclear; however, siRNA-mediated knockdown of HDACs over-
expressed in different cancer cell lines decreased tumour growth and improved 
survival. Taken together, these data support the hypotesis that altered expression 
of HDACs could have an active role in tumour establishment and progression, and 
highlight HDACs as attractive targets for therapeutic intervention. 
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1.3 HDAC INHIBITORS (HDACi) 
1.3.1 HDACi structure and classification 
 
Epigenetic changes identified in tumours can be genome-wide or more restricted 
and can alter the expression or activity of a defined epigenetic regulatory protein. 
These evidences provide a strong rationale for the use of epigenetic-based 
therapies such as HDACi in cancer. A large number of structurally diverse 
HDACi have been purified from natural sources or synthetically produced, and at 
least 11 drugs have entered clinical development. HDACi can be classified 
according to their chemical structure into hydroxamates, cyclic peptides, 
benzamides and fatty acids (Marks, 2010), or according to their specificity for 
various HDAC classes.  
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Table 6: HDACi classification by chemical structure and clinical trial use (Ververis et al., 
2013). 
 
 
The inhibitory effect of a large number of HDAC inhibitors is due to the Zn2+ 
dependency of HDAC enzymes. In fact, many HDACi function by blocking 
access to the active site of HDAC, in a reversible or irreversible manner. The first 
HDACi discovered so far is TSA, a fermentation product of Streptomyces. 
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Originally TSA was used as an anti-fungal agent, but later it was assessed to have 
potent proliferation-inhibitory properties in cancer cells. Today TSA is used 
mainly as a reference substance in research for newly developed HDACi (de 
Ruijter et al., 2003).  
 
 
1.3.2 Biological effects of HDACi on tumour cells 
 
Treatment with HDACi induces tumour cell death, in particular apoptosis, 
differentiation and cell cycle arrest in vitro and in vivo. In addition, activation of 
the host immune response and inhibition of angiogenesis might also have 
important roles in HDACi-mediated tumour regression in vivo. HDACi selectively 
induce apoptosis in tumour cells but not in the normal counterpart, implying a 
therapeutic potential. In fact, normal cells are generally more resistant than 
tumour cells to the pro-apoptotic effects of HDACi. Clinical trials and preclinical 
experiments demonstrated that HDACi can have potent anticancer activities at 
concentrations that are minimally toxic to the host (Bolden et al., 2006; Minucci 
and Pelicci, 2006).  
Although it is well known that HDACi can kill tumour cells, the molecular 
pathways that are responsible for  this effect remain to be fully elucidated. In 
addition, the drug exposure times and dose for in vitro assays can differ markedly 
from those achievable in vivo. Given the pleiotropic biological effects of HDACi, 
it is clear that the effects of these compounds on a single molecular pathway 
cannot mediate apoptosis, cell cycle arrest and differentiation in all cell types. The 
main molecular mediators implied in HDACi effects are listed below. 
 
• Apoptotic pathways. HDAC inhibitors have been reported to activate 
both the death-receptor and intrinsic apoptotic pathways. A large number 
of studies has demonstrated that various Tumour Necrosis Factors (TNF) 
receptor super family members and their ligands are transcriptionally 
activated following HDACi treatment and numerous studies correlate 
HDACi-related apoptosis with induction of one or more extrinsic death 
receptors and/or ligands in human leukaemia cells, including T-ALL cell 
lines Jurkat (Rosato et al., 2003). Moreover, also intrinsic mitocondrial 
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apoptotic pathway seems to play a role in HDACi apoptosis. In this regard, 
HDACi-mediated apoptosis in CEM-CCRF T-ALL cell line through 
intrinsic pathway is due to a selective activation or induction of apoptotic 
proteins belonging to BH3-only proteins (Bim, Bid and Bmf) (Ruefli et al., 
2001). At the same time, HDACi increase levels of Reactive Oxygen 
Species (ROS) and treatment with free radicals scavengers suppress 
apoptotic activity of these drugs in multiple myeloma cell lines. In 
particular, the HDACi SAHA causes an increase in the level of Trx, a 
major reducing protein, in normal cells but not in transformed cells 
(Ungerstedt et al., 2005).  
• Cell cycle arrest and differentiation. Treatment with HDACi is 
associated with cell-cycle arrest at the G1/S. This is often associated with 
the p53-independent induction of CDKN1A, which promotes 
hypophosphorylation of pRb (Sandor et al., 2000). HDACi can also 
mediate G2/M-phase arrest by activating a G2-phase checkpoint, although 
this is a rare event compared with HDACi-induced G1 arrest. Inhibition of 
the cell cycle is a necessary event in cellular differentiation, and numerous 
papers reported on HDACi-related induction of differentiation in AML 
cell lines and AML cells derived from patients (Boissinot et al., 2012; 
Ryningen et al., 2007).  
• Tumour angiogenesis, metastasis and invasion. HDACi have anti-
angiogenic, anti-invasive and immunomodulatory activities in vitro and in 
vivo that can contribute to the inhibition of tumour development and 
progression. The anti-angiogenic properties of HDACi have been 
associated with decreased expression of pro-angiogenic genes including 
vascular endothelial growth factor (VEGF), basic fibroblast growth factor 
(bFGF), hypoxia-inducible factor-1α (HIF1α) (Sasakawa et al., 2003). In 
addition, HDACi have been shown to down-regulate expression of the 
chemokine (C-X-C motif) receptor 4 (CXCR4), which is important for the 
homing of bone-marrow progenitor and circulating endothelial cells to 
sites of angiogenesis. Finally, HDACi have been shown to suppress 
endothelial progenitor cell differentiation supporting a role for HDACi in 
suppressing neovascularization. The putative antimetastatic effect of 
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HDACi might be extended through suppression of matrix 
metalloproteinases (MMPs) (Liu et al., 2003). 
 
 
Fig.2: Schematic representation of anticancer effects of HDAC inhibitors (Ma et al., 2009). 
 
Lee and colleagues investigated the selectivity of the HDACi Vorinostat in 
inducing cell death in cancer cells, but not in normal cells (Lee et al., 2010). 
Interestingly, Vorinostat was able to induce DNA double strand breaks (DSBs) 
both in normal than in tumour cells. Normal cells in contrast to cancer cells repair 
the DSBs despite continued culture with Vorinostat. In transformed cells, 
phosphorylated H2AX (γH2AX), a marker of DNA DSBs, increased with 
continued culture with Vorinostat, whereas in normal cells, this marker decreased 
with time. Further, they found that Vorinostat suppressed DNA DSB repair 
proteins (RAD50, MRE11) in cancer but not normal cells. The DNA damage is 
associated with cancer cell death and this  can explain, in part, the selectivity of 
HDACi in causing cancer cell death. 
 
 
1.3.3 Combination therapy involving HDACi 
 
In addition to their intrinsic cytotoxic properties when tested as a single treatment, 
HDACi have been shown to induce additive cytotoxic effects when used in 
combination with conventional anticancer therapies, such as chemotherapy and 
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radiotherapy. Pre-clinical data in multiple cancer cell lines have shown the 
synergistic effects of HDACi in combination with topoisomerase I inhibitors 
(camptothecin, irinotecan, topotecan), topoisomerase II inhibitors (epirubicin, 
doxorubicin, etoposide, mitoxantrone) and other DNA-damaging agents (cisplatin, 
oxaliplatin, bleomycin) (Nolan et al., 2008). Concerning leukaemias, the HDACi 
Panobinostat potentiated the in vivo effects of vincristine and dexametasone in a 
mouse model of human ALL (Vilas-Zornoza et al., 2012). Regarding 
radiotherapy, there is evidence that HDACi decrease the cell’s capacity to repair 
ionizing-radiations (IR)-induced DNA damage, both at the level of damage 
signalling and by affecting the major DNA repair pathways (Non Homologous 
End Joining and Homologous Recombination), in many different cell types in 
vitro. Tumour cells treated with various HDACi display prolonged resolution of 
IR-induced γH2AX foci, an indicator of impaired double strand breaks repair, 
which is due to impaired recruitment or lower quantities of repair proteins 
(Groselj et al., 2013). For example, in a subcutaneous mouse model of acute 
lymphoblastic leukaemia, treatment with Panobinostat resulted in an increase in 
γH2AX levels in tumour cells (Vilas-Zornoza et al., 2012).  
 
 
1.3.4 HDACi in clinical trials  
 
Currently, there are over 80 clinical trials investigating more than eleven different 
HDACi for both solid and haematological malignancies as  monotherapies or in 
combination with various other antitumor agents. At present, two HDACi – 
Vorinostat (suberoylanilide hydroxamic acid, Zolinza®) and depsipeptide 
(romidepsin, Istodax®) – received approval from the US Food and Drug 
Administration (FDA) for treatment of refractory cutaneous T-cell lymphoma 
(CTCL), and more recently, depsipeptide has gained FDA approval for peripheral 
T-cell lymphoma (PTCL). Many efforts have been made to create chemically 
distinct HDACi, with several ongoing clinical trials in various malignancies, 
many of them focused on haematological pathologies, such as leukaemias, 
lymphomas, and myelodysplastic syndromes. In particular, Vorinostat was FDA-
approved in 2006 for CTCL, which previously could not be treated by other 
drugs. FDA approval was based on two phase II clinical trials with a 30% 
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response rate in patients with CTCL. Vorinostat was generally well tolerated, with 
adverse side effects including diarrhea, fatigue, and nausea (Duvic et al., 2007). 
Similar responses have been observed in patients with relapsed non-Hodgkin’s 
lymphoma and mantle-cell lymphoma (Kirschbaum et al., 2011). Numerous phase 
I and II clinical trials with HDACi in AML patients have been performed. In a 
phase I clinical trial, significant anti-leukaemia activity was observed in patients 
with AML, and Vorinostat effectively inhibited HDAC activity in peripheral 
blood and bone marrow blasts, even if no correlation between acetylated histone 
H3/H4 and clinical response was found (Garcia-Manero et al., 2008). Similar 
results in adults with refractory and relapsed acute leukaemias treated with 
HDACi MS-275 have been reported. In a phase I clinical trial, treatment with MS-
275 induced increase in protein and histone H3/H4 acetylation, p21 expression, 
and caspase-3 activation in bone marrow mononuclear cells (Gojo et al., 2007). At 
variance with the promising clinical responses obtained in patients with 
haematological malignancies, response rates to HDACi in solid cancers have been 
ineffective or modest. Studies in relapsed or refractory breast, colorectal, or non-
small-cell lung cancer showed no response. (Blumenschein et al., 2008; 
Vansteenkiste et al., 2008).  
In addition to those mentioned earlier, some of the more recent HDACi that have 
been tested in patients include Abexinostat, Givinostat, and Mocetinostat.  
In conclusion, although average results of HDACi in clinical trials have been 
modest, it is quite possible that subsets of patients could have a great benefit. 
Future studies are needed to identify possible predictive biomarkers of response to 
HDACi. 
 
 
 
 
 
 
 
 25 
2. AIM OF THE STUDY 
 
Several studies investigated both in vitro and in vivo effects of HDACi in T acute 
lymphoblastic leukaemia (T-ALL). Most of these studies, however, used 
established T-ALL cell lines and they did not identify whether specific signalling 
pathways are perturbed by HDACi. A better knowledge of the molecular events 
underlying HDACi effects will improve clinical application of these drugs. In 
particular, the characterization of specific HDACi targets among transcription 
factors commonly de-regulated in T-ALL, could help to identify subgroups of 
patients more responsive to this treatment. For this purpose, we analysed the 
effects of HDACi on transcription factors relevant in T-ALL pathogenesis using 
both established T-ALL cell lines and patient-derived T-ALL xenografts 
previously obtained in our laboratory. In particular, we focused on transcription 
factors that define four genetic subgroups of T-ALL, including TAL/LMO,  TLX1 
and  TLX3. Furthermore, we included in our analysis members of the Notch 
family (NOTCH1 and NOTCH3) and c-MYB  in view of their transversal role in 
T-ALL. Finally, we strengthened in vitro observations by using HDACi under 
investigation in clinical trials in preclinical models of T-ALL. The long-term goal 
of the project is to investigate the possibility that certain genetic subgroups of T-
ALL could be better candidates for therapeutic treatment with HDACi.  
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3. MATERIALS AND METHODS 
 
3.1 T-ALL xenografts establishment 
 
Primary T-ALL cells (PD-TALL) were obtained from bone marrow of newly 
diagnosed pediatric patients, according to the guidelines of the local ethics 
committees. For xenografts establishment, 6- to 9-weeks-old mice were injected 
intravenously (i.v.) with 10 x 106 T-ALL cells in 300 µl of Dulbecco's Phosphate 
Buffer Saline (PBS). T-ALL engraftment was monitored by periodic blood 
drawings and flow cytometric analysis of CD5 and CD7 markers over a 5-month 
period. NOD/SCID mice were purchased from Charles River (Wilmington, MA). 
Procedures involving animals and their care conformed with institutional 
guidelines that comply with national and international laws and policies (EEC 
Council Directive 86/609, OJ L 358, 12 December, 1987). To test the effects of 
Givinostat (ITF2357) on leukemia cells, NOD/SCID mice were intraperitoneally 
(i.p.) injected with Givinostat (25mg/kg) or PEG400/H2O (vehicle) 2 days after 
leukemic cells injection and administered five days a week. In all experiments, 
mice were inspected twice weekly to detect early signs and symptoms of leukemia 
and blood was drawn to measure T-ALL cell engraftment. 
 
3.2 NOTCH1 and FBW7 mutational analysis  
 
Genomic DNA was extracted from T-ALL cells derived  from xenografts with 
Easy DNA kit (Life Technologies).  NOTCH1 and  FBW7 mutation analysis was 
performed as describe in (Sulis et al., 2008; Thompson et al., 2007) in 
collaboration with Prof. Adolfo Ferrando (Dept. of  Pediatrics, Columbia 
University Medical Center, New York, USA). 
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3.3 Cell lines and in vitro culture conditions 
 
The T-ALL cell lines MOLT-3 and JURKAT were purchased from ATCC. DND 
41 cell lines were kindly provided by A. Ferrando (Columbia University). All T-
ALL cell lines were cultured in RPMI 1640 (EuroClone, Milan, Italy) 
supplemented with 10% FCS (Fetal Bovine Serum, Life technologies, Paisley, 
UK), 10mM HEPES (Cambrex Bioscience, East Rutherford, NJ), 1% Sodium 
Pyruvate, 2 mM L-glutamine and 1% of antibiotic-antimycotic mix (Life 
Technologies). The human embryonic kidney epithelium cell line 293T was 
purchased from ATCC and cultured in Dulbecco modified Eagle medium 
(Euroclone), supplemented with 10% FCS, 10 mM HEPES and 1% of antibiotic-
antimycotic mix (Life Technologies, Paisley, UK). Primary T-ALL cells derived 
from mice spleen were cultured in MEMα medium (Life Technologies) 
supplemented with IL7, SCF, FTL3 (Peprotech, Rocky Hill, NJ) and human 
insulin (Sigma Aldrich, Saint Luis, MO). T-ALL primary cells and cell lines were 
cultured in vitro with  RPMI/MEMα alone (with the appropriate vehicle when 
necessary), or plus the following: 500 nM thricostatin A (Sigma Aldrich), 2 µm 
Givinostat (ITF 2357 - Italfarmaco, Milan, Italy), 500 mM cyclohexamide (Sigma 
Aldrich), 20 µM MG132 (Sigma Aldrich), 20 µM chloroquine (Sigma Aldrich). 
At the indicated time points, the cells were harvested and processed for 
assessment of cell viability, and RNA and protein extraction. 
 
3.4 RNA extraction, reverse transcription PCR (RT-PCR) and 
quantitative RT-PCR (qRT-PCR)  
 
Total RNA was isolated using TRIzol® Reagent according to manufacturer's 
instructions. cDNA was synthesized from 0.5 to 1 µg of total RNA using Super 
Script II Reverse Transcriptase Kit. Reverse transcription was followed by 
quantitative PCR using SYBR Green. mRNA PCRs were performed in an ABI 
Prism 7900HT Sequence Detection System. All reagents were obtained from Life 
Technologies. Results were analysed using the ∆∆Ct method with normalization 
against β2-microglobulin expression. Primers used for q RT-PCR analysis was: 
 
C-MYB-for: 5’-ACCTAGCCCAAGGGTGAACA-3’; 
C-MYB-rev: 5’-TCGAAGGATGACCAGTGGAA-3’; 
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CR2-for: 5'-CTGCGGTTCAGTGTCCACAT-3';  
CR2-rev: 5'-GGTGAAGCCAAACATGCAAGC-3' ;  
DTX-1-for: 5'-GTGGGCTGATGCCTGTGAAT-3';  
DTX-1-rev: 5'-CGAGCGTCCTCCTTCAGCAC-3';  
HES1-for: 5'-GGCGGCTAAGGTGTTTGGAG-3';  
HES-1 rev: 5'-GGAAGGTGACACTGCGTTGG-3';  
NOTCH1-for: 5'-GTCAAGCCAAATATGTCAGC-3' 
NOTCH1-rev: 5'-GCCGGATAAGGTGCCGGAG-3' 
NOTCH3-for: 5’-CAAGGGTGAGAGCCTGATGG-3’;  
NOTCH3-rev: 5’- GAGTCCACTGACGGCAATCC-3’;  
pTα-for: 5’- ATGGTGGTGGTCTGCCTGGT-3’;  
pTα-rev: 5’-AGTTGGTCCAGGTGCCATCC-3’;  
β2-microglobulin-for 5'-TGCTGTCTCCATGTTTGATGTATCT-3';  
β2-microglobulin-rev: 5'-TCTCTGCTCCCCACCTCTAAGT-3'.  
 
Expression levels of target genes in short term treatment experiments were 
analysed by Real Time Ready custom panels (Roche Diagnostics, Penzberg, 
Germany). 
 
 
3.5 Gene Expression profiling and classification of T-ALL 
xenografts 
 
Total RNA was extracted from the spleen using Trizol® reagent (Life 
Technologies), according to the manufacturer’s instruction. RNA concentration 
was determined using NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies Inc, Wilmington, DE). The instruments provided the sample 
concentration in ng/µl and the absorbance of the sample at 260nm and 280nm. 
The ratio (260/280) ranging from 1.8 to 2.1 indicated good quality of RNA (ratio 
< 1.8 means protein contamination and ratio > 2.1 RNA degradation and truncated 
transcripts). RNA quality and purity control was assessed with the Agilent 
Bioanalyzed 2100 (Agilent Technologies, Waldbronn, Germany) using 
“Eukaryote total RNA Assay”. To perform gene expression experiments, 
extremely high quality of total RNA was used.  
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Only RNA samples that passed the high quality controls were diluted to 100 ng in 
a total volume of 3 µl DEPC treated water to perform gene expression 
experiments. In vitro transcription, hybridization and biotin labelling were 
performed according to GeneChip 3’IVT Express kit protocol (Affymetrix, Santa 
Clara, CA). The Affymetrix GeneChip Scanner was used to measure all intensities 
of the signals of each probe set on the GeneChip and stores all signals in a .DAT 
file (Raw image). Integrated software converts all raw signals into numbers, 
which were stored in a .CEL file. All GEP profiles used in these experiments were 
assessed for their comparability and quality, using different quality controls: Scale 
Factor, number of present calls, internal probe calls, Poly-A controls and the ratio 
GAPDH/β-actin 3’/5’.  
Microarray data (.CEL files) were analyzed using Command Expression Console 
(Affymetrix). R-Bioconductor (Version 2.15.3) was used to analyse the .CEL files 
data. Supervised classification (PAM_predictive analysis of microarrays) was 
used to construct a predictive algorithm able to classify samples for the main 
cytogenetic subgroups (TALLMO, TLX1, TLX3, HOXA) that characterize the T-
ALL. Predictive algorithm was developed on a “training” data set, where the 
categories to which objects belonged were known and evaluated on an 
independent “test” data set, in which objects were assigned to previously defined 
categories. 
3.6 Retroviral vectors production 
 
Viral vectors were generated using 293T cell lines due to their high transfection 
capacity. In particular, cells were transiently transfected with 3 plasmids using 
calcium phosphate transfection method. The viral vectors produced in this way, 
belong to HIV-based vectors called SIN (self- inactivating). Plasmids used for 
viral production are listed below: 
• A plasmid coding the transgene of interest; 
• A packaging plasmid (gag-pol gpt), coding HIV gag and pol genes; 
• pHCMV-G plasmid driving the expression of Vescicular Stomatitis Virus 
protein G (VSV-G). This protein of the envelope allows to extend the 
tropism of the virus. 
Expression constructs used in this project: 
 31 
• pCEG and pNOTCH3 CEG: NOTCH3 ICD retroviral over-expressing 
vectors; 
• pMIGRI and pNOTCH1 MIGRI: NOTCH1 ICD retroviral over- 
expressing vectors. 
 
3.7 Transduction of T-ALL cells 
 
JURKAT cells were transduced with VSVG-pseudotyped NOTCH3-expressing or 
NOTCH1-expressing retroviruses. Briefly, 1x106 cells were incubated at 37°C 
O.N. with 1x108 virus particles and Protamine Sulfate. The day after, cells were 
washed and cultured in fresh medium. After expansion, cells were analyzed for 
high green fluorescent protein expression by flow cytometry analysis and used for 
caspase assay and western blot analysis. 
 
3.8 Caspase assay 
 
In rescue experiments, apoptosis was evaluated measuring caspase 3-7 activity 
with CaspaseGlo 3/7 assay kit (Promega, Madison, WI). These members of the 
cysteine aspartic acid-specific protease (caspase) family are key effectors of 
apoptosis in mammalian cells. The assay provides a luminogenic caspase-3/7 
substrate, which contains the tetrapeptide sequence DEVD, in a reagent optimized 
for caspase activity. Adding a single Caspase-Glo 3/7 reagent results in cell lysis, 
followed by caspase cleavage of the substrate and generation of a luminescent 
signal, produced by luciferase (Figure 3). Luminescence is proportional to the 
amount of caspase activity present.  
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Fig. 3: Caspase-3/7 cleavage of the luminogenic substrate containing the DEVD sequence. 
Following caspase cleavage, a substrate for luciferase (aminoluciferin) is released, resulting in the 
luciferase reaction and in the production of light. 
 
 
3.9 MTS assay 
 
Proliferation rate of T-ALL cells after HDAC inhibition were measured using 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega). The 
MTS tetrazolium compound (Owen’s reagent) is bioreduced by cells into a 
colored formazan product that is soluble in tissue culture medium (Figure 4). This 
conversion is presumably accomplished by NADPH or NADH produced by 
dehydrogenase enzymes in metabolically active cells. The quantity of formazan 
product as measured by the absorbance at 490nm is directly proportional to the 
number of living cells in culture. 
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Figure 4: Structures of MTS tetrazolium and its formazan product. 
 
 
3.10 Cytofluorimetric analysis 
 
Anti-human FITC-conjugated CD5 and PE-Cy5-conjugated CD7 antibodies 
(Coulter, Fullerton, CA) were used for the detection of T-ALL cells in blood, 
spleen and bone marrow samples. Apoptosis was evaluated by the Annexin-V-
FLUOS Staining Kit (Roche Diagnostics). To test the effective transduction of T-
ALL cells with retroviral vectors, percentage of green fluorescent protein (GFP) 
positive cells was measured 48 h after transduction by cytometric analysis. 
Indeed, both expression plasmids (N3 CEG, N1 MIGRI and control) have GFP 
reporter gene. Samples were analyzed on Beckman Coulter EPICS-XL Flow 
Cytometer (Coulter) or BD LSRII Flow Cytometer (BD Biosciences, San Jose, 
CA). 
 
3.11 Western Blot analysis 
 
Cells were resuspended in lysis buffer (NP-40 1%, NaCl 150 mM, Tris HCl pH7.5 
50 mM, EDTA 2mM, NaF, Na3VO4 and protease inhibitor cocktail) and lysates 
obtained were quantified using Quantum protein Assay (Euroclone). About 30 µg 
of proteins were denaturated and loaded in a midi polyacrylamide gel 4-12% (Life 
Tecnologies). Separated proteins were transferred for 2 h at 400mA on a 
nitrocellulose membrane  (GE Health Care, Glattbrugg, Switzerland). Membranes 
were saturated O.N. at 4°C with PBS - 0,1% Tween - 5% - milk and then 
incubated with primary antibody according to manufacturer’s instructions. 
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In this work, these primary antibodies were used:  
• Rabbit anti ACTIN (Sigma Aldrich); 
• Mouse anti TUBULIN (Sigma Aldrich); 
• Rabbit anti PARP (Cell Signalling, Danvers, MA); 
• Rabbit anti NOTCH3 (Abcam, Cambridge, UK); 
• Rabbit anti NOTCH1 C44H11(Cell Signalling); 
• Mouse anti c-MYB (Merck-Millipore, Billerica, MA); 
• Mouse anti c-MYC (Merck-Millipore); 
• Mouse anti Acetylated α TUBULIN (Santa Cruz Biotechnologies, Dallas, 
Texas); 
• Mouse anti TAL1 (Merck-Millipore); 
• Rabbit anti LMO2 (Abcam); 
• Rabbit anti TLX1 (Sigma Aldrich); 
• Mouse anti TLX3 (Sigma Aldrich); 
• Rabbit anti NOTCH1 ICD Val1744 (Cell Signalling); 
• Rabbit anti p16 (Abcam). 
 
Secondary antibodies (GE Healthcare) are conjugated with horseradish 
peroxidase. When reaction mix, containing Luminol, joins with peroxidase, the 
substrate is oxidated resulting in emission of light at 425nm. For detection, 
Western Lightning plus ECL reagents (Perkin Elmer, Waltham, MA) were used. 
The signal emitted by the reaction was acquired by acquisition imagine system 
ChemiDoc XRS (Bio Rad, Hercules, CA). 
3.12 Statistical analysis  
 
Results were expressed as mean value ± SD. Statistical analysis of data was 
performed using Student's t-test or Mann-Whitney test. Differences were 
considered statistically significant when P ≤ 0.05. 
 
 35 
4. RESULTS 
 
4.1 Functional effects of HDAC inhibition in T-ALL cells 
 
HDACi have moderate to strong therapeutic activity in several haematological 
malignancies and according to previous studies, HDACi are potent inducers of 
apoptosis in leukaemia cells (Aldana-Masangkay et al., 2011; Vilas-Zornoza et 
al., 2012). In order to investigate the therapeutic potential of HDACi in the 
context of T-ALL, we treated with the pan-HDAC inhibitor Tricostatin A (TSA) 
0.5 µM for 24 h a panel of established T-ALL cell lines (DND 41, MOLT3 and 
JURKAT) and xenografts cells derived from primary leukemic samples from 
patients. The concentration of TSA was based on published data on leukaemia 
cells in vitro (Chambers et al., 2003; Palermo et al., 2012). We successfully 
established mice xenografts and treated them ex vivo with HDACi. Briefly, 
immunodeficient NOD/SCID mice were injected intravenously with 1x107 
cells/mouse derived from bone marrow of paediatric T-ALL patients. In order to 
track tumour burden, regular blood drawings and cytofluorimetric analysis were 
performed to analyse the percentage of leukemic cells in circulation. At the 
appearance of signs of illness, mice were sacrificed. The leukemic cells were 
collected from the spleen, infiltrated > 90%, and used for in vitro studies with 
HDAC inhibitors. We chose to analyse the effects of HDACi on seven xenografts 
with distinct molecular and clinical phenotypes such as NOTCH1 mutation status, 
genetic subgroup, prednisone sensitivity and MRD risk (See table 7). 
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Table 7: Paediatric T-ALL patients were classified for differentiation phenotype, risk 
(according to the MRD classification) and response to therapy. All patients were aged between 
3-16 years. Mutational status of NOTCH1 and FBW7 and the genetic subgroup are also reported. 
[MR= medium risk, HR= high risk; PGR= prednisone good responder, PPR= prednisone poor 
responder; HD= heterodimerization domain, PEST= proline-glutamic acid-serine-threonine-rich 
domain, TAD= C-terminal transcription activation domain]  
 
 
Inhibition of HDACs exerted strong pro-apoptotic effects in all the cell lines and 
T-ALL cells from xenografts tested (Fig.5). These effects were not associated 
with the mutational status of NOTCH of T-ALL cells (Fig. 5B).  
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Fig.5: HDACi-mediated induction of apoptosis in T-ALL cells. T-ALL cell lines (A) or 
primary T-ALL cells (B) were treated in vitro with TSA (0.5 uM) for 24 h. Induction of apoptosis 
was measured by flow cytometric analysis of Annexin V staining (* P<0.05, ** P<0.01, *** P 
<0.001, mean ± SD of three independent experiments). 
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To study the effect of HDAC blockade on proliferation in our cell contest, we 
assessed MOLT3 proliferation rate using both a metabolic assay (MTS) and cell 
count. As shown in Fig.6, MOLT3 treated with TSA decreased proliferation 
compared to controls both at 24 h and 30 h. Later time points were not considered 
due to the reduced viability of the cells. 
 
 
                      
 
Fig 6: HDACi-induced inhibition of proliferation in MOLT3. MOLT3 were treated with TSA 
(0.5 µM). Cell number (A) and metabolic activity (B) were assessed at 3, 8, 24 and 30 h 
respectively by cell count and MTS assay (* P<0.05, ** P<0.01, *** P <0.001, mean ± SD of three 
independent experiments). 
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4.2 HDAC inhibitor TSA down-regulates relevant T-ALL 
transcription factors protein levels 
 
In order to investigate the effect of HDACi on the expression of transcription 
factors associated to T-ALL leukaemogenesis, the T-ALL cell lines DND 41, 
MOLT3 and JURKAT were treated in vitro with TSA 0.5 µM. After 16 h of 
treatment, whole cell lysates were extracted  and analysed for the protein levels of 
a selected panel of transcription factors (NOTCH1, NOTCH3, c-MYB, TLX1, 
TLX3, LMO1, LMO2 and TAL1) by western blot. Accumulation of acetylated α 
tubulin, a direct target of HDAC6, was used as a read-out of HDAC activity 
inhibition. As expected, treatment with TSA for 16 h resulted in the increase of 
acetylated α tubulin  (Fig.7). 
Interestingly, we observed that TSA decreased protein levels of NOTCH1, 
NOTCH3, c-MYB and TAL1 in all the cell lines tested. On the contrary, LMO2, 
TLX3 and TLX1 levels were not significantly affected by HDAC inhibition (Fig. 
7).  
 
                   
 
 
Fig.7: Effects of HDACi on transcription factors relevant in T-ALL. DND 41, MOLT3 and 
JURKAT were treated with TSA (0.5 µM) for 16 h and protein levels were analysed by western 
blot. The housekeeping protein ACTIN was used as loading control. Tubulin acetylation was used 
as a marker of HDAC inhibition. 
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To confirm the results obtained, we treated ex vivo T-ALL xenografts cells with 
TSA. After 16 h of treatment, NOTCH1, NOTCH3, c-MYB and TAL1 protein 
level displayed a marked reduction, whereas TLX3, TLX1 and LMO2 expression 
was not altered by TSA (Fig. 8) 
 
          
 
 
Fig.8: Effects of TSA treatment on transcription factors expressed in primary T-ALL cells. 
T-ALL cells were recovered from spleen of xenografted mice and were treated in vitro with TSA 
(0.5 µM) for 16 h. Protein levels were analysed by western blot.  
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4.3 Differential effects of HDAC inhibition on mRNA expression 
of NOTCH1, NOTCH3 and c-MYB 
 
To investigate whether the TSA-induced suppressive effect at protein level was 
associated with inhibition of transcription, we analysed the mRNA levels of 
NOTCH1, NOTCH3 and c-MYB upon HDACi treatment. TAL1 was excluded 
from this analysis, as its transcription has been previously reported to be 
suppressed by HDACi in ALL cells (Cardoso et al., 2011). Interestingly, c-MYB 
mRNA displayed more than 80% reduction in all cell lines tested. On the 
contrary, we obtained heterogeneous results for NOTCH1 and NOTCH3. In fact, 
upon TSA-treatment mRNA expression of the two NOTCH receptors was 
significantly altered in DND 41 but not in MOLT3 and in JURKAT cells (Fig. 
9A). Similar results were obtained with three representative human T-ALL 
xenografts (PD-TALL6, PD-TALL8 and PD-TALL9) (Fig. 9B). This result 
suggests that NOTCH1 and NOTCH3 could be either post-transcriptionally and/or 
post-translationally regulated by TSA depending on the cell line analysed. 
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Fig 9: Transcript levels of NOTCH1, NOTCH3 and c-MYB in T-ALL cell lines after HDAC 
inhibition.  T-ALL cell lines (A) or primary T-ALL cells (B) were treated with TSA (0.5 uM) for 
16 h and mRNA levels of NOTCH1, NOTCH3 and c-MYB were analysed by qRT-PCR. 
Statistically significant differences are indicated (* P<0.05, ** P<0.01, *** P <0.001, mean ± SD 
of three independent experiments).  
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In line with western blot analysis, blockade of HDAC activity decreased the 
expression of NOTCH target transcripts, such as pTα, CR2 and DTX-1, thus 
indicating attenuation of NOTCH signalling (Fig 10).  
 
 
               
           
Fig 10: NOTCH target genes expression after TSA treatment.  T-ALL cell lines (A) or T-ALL 
cells from xenografts (B) were treated with TSA (0.5 µM) for 16 h and mRNA levels of NOTCH 
target genes (pTα, CR2, DTX-1, HES1) were analysed by qRT-PCR (* P<0.05, ** P<0.01, *** P 
<0.001, mean ± SD of three independent experiments).  
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4.4 Forced NOTCH1 and NOTCH3 expression partially prevents 
T-ALL cell death induced by HDAC inhibition  
 
The transcription factors NOTCH1, NOTCH3 and c-MYB are known to play a 
fundamental role in cell death evasion (Lahortiga et al., 2007; Lewis et al., 2007; 
Sarvaiya et al., 2012; Zhou et al., 2011). Based on this, we next investigated 
whether down-regulation of these transcription factors was the basis of TSA-
induced apoptosis in T-ALL cells. To this aim, we analysed pro-apoptotic effects 
of TSA upon forced expression of NOTCH1 or NOTCH3 in T-ALL cells. We 
transduced JURKAT cells with retroviral vectors driving the expression of 
NOTCH1 and NOTCH3 intracellular domain (ICD), the constitutively active form 
of the transcription factor (Fig.11A). Forced expression of NOTCH1 and 
NOTCH3 significantly reversed the induction of apoptosis mediated by TSA in T-
ALL cells, measured by caspase assay and the ratio cleaved:unclived PARP (Fig. 
11 B and C). These results suggest that HDACi promote apoptosis in T-ALL cells 
partly via suppression of NOTCH1 and NOTCH3 activity. Similar rescue 
experiments are undergoing with c-MYB. 
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Fig. 11: Forced expression of NOTCH1 and NOTCH3 ICD reduced apoptosis in JURKAT 
cells. A) JURKAT were transduced with a retroviral vector expressing NOTCH1 or NOTCH3 
intracellular domain (RV-N1 and RV-N3) or with the control vector (RV-CNTR). Over-expression 
was monitored by western blot. B) JURKAT cells transduced by RV-CNTR or RV-N1/RV-N3 
vectors were treated with TSA 0.5 µM for 24 h. Apoptosis was monitored by caspase 3-7 assay 
and, for NOTCH3, by western blot analysis of cleaved PARP (C). TSA/DMSO luminescence ratio 
are reported (**p<0.01, three independent experiments).  
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4.5 HDACi-mediated NOTCH3 down-regulation in T-ALL cells is 
dependent on increased protein degradation 
 
Several reports indicate that HDACi can induce degradation of oncogenes and 
other cellular proteins by affecting protein stability. To test whether protein 
degradation has a role in the effects of HDACi on c-MYB and NOTCH3 protein 
levels, we treated MOLT3 cells with cyclo-heximide (CHX), a well-known 
protein translation inhibitor. The half-life of c-MYB, which is roughly 8 h in 
MOLT3 cells, was not significantly altered by treatment with TSA, indicating that 
this HDACi lacks major effects on c-MYB protein stability. In contrast, NOTCH3 
protein levels decreased faster upon CHX treatment in the presence of TSA (Fig. 
12). This result indicates that HDACi affects NOTCH3 protein stability, implying 
a post-translational mechanism of regulation. 
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Fig.12: HDACi increased NOTCH3 protein degradation.  A) MOLT3 were treated with CHX 
(500 µM) or with CHX (500 µM) and TSA (0.5 µM). At 1, 5, 8 and 16 h protein levels of c-Myb 
and NOTCH3 were analysed by Western Blot. A representative Blot is reported. C-MYB (B) and 
NOTCH3 (C) protein expression were measured by densitometric analysis and normalized to 
ACTIN. The graphs represent the mean of three independent experiments (**p<0.01). 
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4.6 HDACi-mediated NOTCH1 and NOTCH3 protein down-
regulation in T-ALL cells is driven by lysosomal degradation 
 
 
In mammalian cells, two major protein degradation pathways are known: the 
proteasome, which degrades mainly cytosolic proteins, and the lysosome, which 
accounts for membrane proteins turnover (Clague and Urbe, 2010). To investigate 
the molecular mechanism underlying increased NOTCH protein degradation, we 
treated MOLT3 cells with proteasome or lysosome inhibitors. Protein levels of the 
full-length NOTCH receptors were rescued using the lysosome inhibitor 
chloroquine (CHL), suggesting involvement of the endocytic pathway, whereas 
the proteasome inhibitor MG132 had minimal effects on NOTCH1 full-length 
levels and further reduced NOTCH3 full-length levels. As expected based on our 
previous findings, lysosome inhibition did not affect c-MYB protein levels 
(Fig.13 A). To test inhibition of proteasomal activity by MG132, we treated 
MOLT3 with MG132 and analysed protein levels of the transcription factor C-
MYC, which is normally degraded by proteasome. As expected, C-MYC protein 
levels increased after proteasomal inhibition (Fig. 13 B).  
         
          
Fig.13: Lysosome inhibitor impaired NOTCH1 and NOTCH3 protein degradation.  A) 
MOLT3 were treated with TSA 0.5 µM, CHL 20 µM or MG132 20 µM for 16 h and western blot 
analysis were performed. Numbers below the bands indicate densitometric analysis of NOTCH3 
normalized to ACTIN.  B) As control of MG132 activity, MOLT3 were treated with MG132 (20 
µM for 8 h) and c-MYC protein levels were analysed by western blot.   FL, full length. 
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4.7 Assessment of Givinostat effects on T-ALL cells in vitro 
 
We sought to confirm the anti-tumour activity of TSA, using Givinostat, a pan-
HDACi under investigation in clinical trials. Givinostat has been tested  in phase 
II clinical trials for several haematological malignancies (including relapsed 
leukaemias and myelomas), and has been granted orphan drug designation in the 
EU  for treatment of systemic juvenile idiopathic arthritis and polycythaemia vera. 
We first assessed the in vitro activity of Givinostat on T-ALL cell lines and 
primary T-ALL cells from xenografts. We treated cells with Givinostat 2 µm, 
according to Italfarmaco's instructions. Similarly to TSA, treatment with 
Givinostat determined a substantial reduction of NOTCH1, NOTCH3, c-MYB 
and TAL1 protein levels. In contrast, LMO2, TLX1 and TLX3 levels were 
apparently not modulated (Fig.14). In addition, in some cases we analysed protein 
levels of p16INK, known as CDKN2A (Cyclin-dependent kinase inhibitor 2A), a 
tumour suppressor protein, implicated in the regulation of cell cycle. Both in T-
ALL cell lines and primary  cells (Fig.12), p16 INK protein levels increased upon 
Givinostat treatment.  
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Fig.14: Effect of Givinostat on transcription factors expressed in T-ALL cells. T-ALL cell 
lines (A) and primary T-ALL cells from  xenografts (B) were treated in vitro with Givinostat (2 
µM) for 16 h and protein levels were analysed by western blot.  
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Finally, T-ALL cell lines and primary cells treated with Givinostat invariably 
showed increased apoptosis and impaired cell cycle progression (Fig.15). 
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Fig.15: Givinostat increased apoptosis and impaired proliferation of T-ALL cells. T-ALL cell 
lines (A) or primary T-ALL cells (B) were treated in vitro with Givinostat (2 µM) for 24 h. Levels 
of apoptotic cells were measured by flow cytometric analysis of annexin V staining. (* P<0.05, ** 
P<0.01, *** P <0.001, three independent experiments). C) MOLT3 were treated with Givinostat (2 
µM). At 3, 8, 24 and 30 h metabolic activity  (an indirect reed-out of cells number) was analysed 
by MTS assay (** P<0.01, three independent experiments). 
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4.8 Therapeutic effects of Givinostat in T-ALL xenografts 
 
We next asked whether primary samples belonging to different T-ALL subgroups 
could respond differentially to long term treatment with Givinostat in vivo, 
considering its effect on the expression of relevant transcription factors. In 
particular, for these experiments, we choose the following four xenografts 
belonging to different T-ALL genetic subgroups: PD-TALL12 (TAL-LMO), PD-
TALL9 (TAL-LMO), PD-TALL8 (TLX1) and PD-TALL16 (TLX3). Since TAL-
LMO subgroup is the most represented subgroup in T-ALL, it was easier to obtain 
xenografts belonging to this subgroup. On the other hand, since none of the 
xenografts established in our laboratory belongs to the HOXA subgroup, it was 
not possible to study the influence of HDACi treatment on this specific genetic 
subset.  
T-ALL cells were injected i.v. in NOD/SCID mice at 5x106 cells/mouse. 
Givinostat (25mg/kg) or PEG400/H20 (vehicle) were administrated 5 days per 
week and treatment started 2 days after cell injection. The levels of blasts in the 
blood, spleen and bone marrow were evaluated by flow cytometric analysis 
(staining with anti-CD5 and anti-CD7, characteristic markers used to identify 
human T-ALL cells). At the appearance of signs of illness in control mice, both 
groups were sacrificed and therapeutic response was evaluated by analysis of 
percentage of leukemic cells and levels of apoptosis in bone marrow and spleen.  
The experimental design is reported below. 
 
 
 
 
 
The therapeutic effects of Givinostat were very variable among the four 
xenografts tested. PD-TALL8 and PD-TALL16 were best responders to the 
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treatment while PD-TALL12 and PD-TALL9 showed respectively partial and no 
measurable response. In particular, PD-TALL8 (TLX1) treated mice displayed a 
significant reduction in the percentage of CD7+ cells in peripheral blood (Fig. 16 
A) as well as in spleen and bone marrow at sacrifice (Fig. 16 B) compared to 
controls. Treated mice showed an increased in apoptosis in the spleen and albeit 
less prominent, in the bone marrow, consisting with the pro-apoptotic effects of 
Givinostat in vitro (Fig. 16 C). At sacrifice, spleen size was comparable in treated 
and control mice (Fig. 16 D). 
 
 
 
Fig.16: Therapeutic effects of Givinostat in PD-TALL8 xenografts (TLX1). A) Measurement 
of circulating blasts by flow cytometry in the blood. B) Percentage of leukemic cells in the spleen 
and bone marrow at sacrifice. C) At sacrifice, levels of apoptotic leukemic cells in the spleen and 
in the bone marrow were measured by annexin V labelling and flow cytometric analysis (n=6 
mice/group) (* P<0.05, ** P<0.01, *** P <0.001). 
 
 
PD-TALL16 (TLX3) also responded well to treatment. Also in this case, treated 
mice displayed a significant reduction of circulating blasts and in the percentage 
of infiltrating cells in spleen and bone marrow (Fig.17 A and B). Apoptosis levels 
in spleen and bone marrow increased in treated mice and were associated with a 
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significant decrease in spleen weight (Fig.17 C and D). As for PD-TALL8, the 
effect of treatment was more pronounced in the spleen than in the bone marrow.  
 
 
 
Fig. 17: Therapeutic effect of Givinostat in PD-TALL16 xenografts (TLX3). (n=6 mice/group) 
(* P<0.05, ** P<0.01, *** P <0.001). 
 
 
Concerning PD-TALL12 (TAL-LMO), treatment with Givinostat determined a 
reduction over time of the percentage of CD7+ cells in the peripheral blood and a 
modest albeit significant reduction of leukemic cells infiltrating the spleen (from 
80% to 30% of infiltrating cells). On the contrary, Givinostat did not decrease the 
level of infiltration of bone marrow, that was comparable between treated and 
control mice (Fig. 18 A and B). Evaluation of apoptosis in T-ALL cells harvested 
from the spleen of mice confirmed an increase in cell death (Fig. 18 C). 
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Fig. 18: Therapeutic effects of Givinostat in PD-TALL12 xenografts (TAL-LMO). (n=6 
mice/group) (* P<0.05, ** P<0.01, *** P <0.001). 
 
 
 
PD-TALL9, another leukaemia of the TAL-LMO subgroup, displayed less 
prominent effects compared to the other TAL-LMO xenograft  PD-TALL12. On 
one hand, HDAC inhibition delayed T-ALL cells engraftment, as indicated by the 
significant reduction in the levels of CD7 positive cells in the blood of treated 
mice and by the decrease in spleen weight at sacrifice compared to controls (Fig. 
19 A and D). On the other hand, there was no difference in the percentage of 
infiltrating and apoptotic cells in the spleen and the bone marrow of treated mice 
compared to controls (Fig. 19 B and C). Therefore, in PD-TALL9 Givinostat 
modestly delayed infiltration of spleen and bone marrow by leukemic cells, 
without affecting their viability. 
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Fig.19: Therapeutic effects of Givinostat in PD-TALL9 xenografts (TAL-LMO). (n=5 
mice/group) (* P<0.05, ** P<0.01, *** P <0.001). 
 
 
In conclusion, down regulation of TAL1 protein induced by HDACi in vitro does 
not appear to correlate with therapeutic response to long-term treatment in vivo in 
TAL/LMO xenografts. On the other hand, TLX-driven xenografts PD-TALL8 and 
PD-TALL16 had better response to Givinostat, although neither TLX1 nor TLX3 
protein levels were affected by HDAC inhibitors in vitro. These results suggest 
that TLX1/TLX3 T-ALL samples could be better responders to Givinostat. 
 
 
 
 
 
 
 58 
4.9 Short term treatment in vivo using Givinostat  
 
Since TLX 1 and 3 act as transcriptional repressor forming a complex with 
HDACs, we  investigated whether HDACi could modulate TLX target genes 
expression.  For this purpose, we performed short-term treatment in NOD/SCID 
mice with Givinostat. For this experiment, we used three primary xenografts used 
in the long-term treatment experiment. Briefly, T-ALL cells were injected i.v. in 
NOD/SCID mice at 5x106 cells/mouse. Givinostat (25mg/kg) or PEG400/H20 
(vehicle) were administrated i.p once. The drug was administered when mice had 
full-blown leukemia, meaning percentage of blasts in the peripheral blood, bone 
marrow and spleen exceeding 10%, 70% and 80%, respectively (Fig. 20-22). 
Mice were sacrificed 6 h after treatment. Spleen and bone marrow infiltration by 
T-ALL cells at sacrifice was very high and comparable between treated and 
untreated mice (Fig. 20-22). The experimental setting is represented in the 
following schematic drawing: 
 
 
 
 
Cells were obtained from the spleen of the mice at sacrifice and mRNA levels of 
several TLX target genes were analysed by qRT-PCR. To confirm the efficacy of 
HDAC inhibition in vivo, we measured the acetylated form of α tubulin (Fig. 20-
22). 
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Fig. 20: Engraftment of PD-TALL8 cells in NOD/SCID mice. A) Leukaemia engraftment in 
NOD/SCID mice was evaluated by peripheral blood drawings analysis at day 20, 27 and 32 after 
T-ALL cells injection. B) Spleen and bone marrow were completely infiltrated at sacrifice 32 days 
after leukemic cells injection. C) Accumulation of acetylated α tubulin, was measured as a reed-
out of HDAC activity inhibition by western blot analysis. 
 
 
 
 
 
 
 
 
 
Fig. 21: Engraftment of PD-TALL16 cells in NOD/SCID mice 
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Fig. 22: Engraftment of PD-TALL12 cells in NOD/SCID mice 
 
 
 
We analysed expression levels of a panel of TLX-related target genes including 
ALDH1A1 (Rice et al., 2008), RUNX1, GBP5, PTPN14, PLXD1 (Della Gatta et 
al., 2012) and CCR7 (Rakowski et al., 2011). Moreover, we assessed the 
expression of several TAL1 and c-MYB target genes, including TRIB2, STAT5A, 
BIM1 and GATA2 (Lorenzo et al., 2011; Sanda et al., 2012; Waldron et al., 2012) 
and NOTCH target genes, including CR2, DTX1 and pTα. Interestingly, 
expression of several TLX-target genes was modulated in treated mice compared 
to controls. In particular, the most up-regulated genes in all xenografts analysed 
were ALDH1A1, GBP5 and CCR7, confirming the effect of Givinostat on TLX 
signalling. With regard to TAL1 and c-MYB-related target genes, STAT5A was 
reduced in PD-TALL12 and PD-TALL8, whereas BIM1 was down-regulated in 
PD-TALL8. The NOTCH target genes most regulated in vitro (CR2, DTX1 and 
pTα) did not display significant reductions in mRNA levels in vivo (Fig. 23). 
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Fig. 23: Evaluation of TAL1, c-MYB, NOTCH and TLX target genes expression. T-ALL cells 
were recovered from mice spleen and mRNA expression of several target genes were assessed in 
PD-TALL8, PD-TALL16 and PD-TALL 12 (A, B and C) by qRT-PCR (n=6 mice/group) (* 
P<0.05, ** P<0.01, *** P <0.001). 
 62 
 
 
 63 
5. DISCUSSION 
 
In recent years, HDACi have emerged as candidate new drugs for cancer 
treatment. The therapeutic potential of HDACi stems from their higher cytotoxic 
activity against tumour cells compared with normal cells. Although numerous 
studies on HDACi have been published during the last decade, the mechanisms 
underlying their anti-tumour effects are still substantially unknown. In particular, 
the oncogenic pathways modulated by these compounds have not been fully 
elucidated. This lack of knowledge prevented so far identification of a subset of 
patients who might be responsive to these drugs.  
 
The goal of my project was to investigate the impact of HDAC inhibitors on 
signalling pathways relevant in T-ALL in vitro and investigate whether this 
knowledge might predict therapeutic efficacy of these drugs in preclinical models 
of T-ALL. 
The first step was to evaluate the pro-apoptotic and anti-proliferative effect of a 
canonical HDACi (TSA) in vitro in T-ALL cell lines and in a panel of primary T-
ALL cells recovered from xenografts. TSA induced high levels of apoptosis in all 
samples, a finding which was somewhat at odds with our working hypothesis. 
This effect was not associated with the genetic subgroup of T-ALL, the NOTCH1 
mutational status or other genetic features of xenografts. Unfortunately, primary 
cells from xenografts do not proliferate in vitro, thus preventing the possibility to 
measure anti-proliferative effects of TSA.  
 
We next investigated the effect of HDACi on several transcription factors implied 
in T-ALL pathogenesis (TAL1, LMO2, TLX1, TLX3, c-MYB, NOTCH1 and 
NOTCH3). Although some recent studies reported the effects of HDACi on 
individual transcription factors (TAL1 and NOTCH3) (Cardoso et al., 2011; 
Palermo et al., 2012), this is the first comprehensive work which sets out to 
analyse the effect of HDACi on key signalling pathways in T-ALL. Our results 
disclosed regulation of several transcription factors by various mechanisms, 
including both transcriptional (in the case of TAL1 and c-MYB) and post-
transcriptional (in the case of NOTCH) levels.  Results were further validated by 
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measurements of expression levels of certain target genes of the various 
transcription factors. In the case of NOTCH, we unexpectedly observed TSA-
mediated induction of HES1, one of the most important effectors of Notch 
signalling. However, when we checked HES1 protein levels we found them 
decreased after TSA treatment in both MOLT3 and DND 41 cells (data not 
shown). This observation could suggest the existence of compensatory circuits, in 
which low HES1 protein levels up-regulate HES1 transcription. Concerning 
TLX1 and TLX3, HDACi probably affect the repressor complex formation on 
TLX target genes promoters, blocking HDACs activity. Thus, protein levels were 
not altered by HDACi, but there was a modulation of the genes downstream 
TLX1 and 3, detected by qRT-PCR in short-term experiments in vivo, as shown in 
Fig. 23.  
 
But are modulations of transcription factors essential to the pro-apoptotic activity 
of the drug? In the case of TAL1, its contribution to HDACi-induced apoptosis 
has been recently demonstrated in T-ALL by Cardoso et al. (Cardoso et al., 2011) 
To investigate this in the case of other transcription factors modulated by HDACi, 
we performed rescue experiments. We found that over-expression of the active 
forms of NOTCH1 and NOTCH3 prevents apoptosis upon TSA treatment. This 
result suggests a substantial contribution of NOTCH signalling in this 
phenomenon, although it should be noted that T-ALL cells bearing NOTCH1 
activating mutations had similar levels of apoptosis as NOTCH1 wild-type cells. 
We are currently using a similar approach to investigate the role of c-MYB in 
HDACi-induced cell death, considering the involvement of this oncoprotein in T-
ALL (Clappier et al., 2007; Lahortiga et al., 2007; Sarvaiya et al., 2012; Stenman 
et al., 2010).  
 
Furthermore, we investigated the mechanism underlying the post-transcriptional 
regulation of NOTCH1 and NOTCH3 by HDACi. Interestingly, NOTCH1 and 
NOTCH3 down-regulation upon TSA treatment was rescued by a lysosome 
inhibitor, which suggests involvement of the endocytic pathway. This is in line 
with a previous work that demonstrated an increase in protein degradation of the 
Epidermal Growth Factor Receptor (EGFR) by the endocytic compartment 
following treatment with HDACi. In this study, HDACi increased microtubule 
acetylation and accelerated microtubule-dependent movement of EGFR-bearing 
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vesicles to the lysosome by an HDAC6-mediated mechanism (Gao et al., 2010). 
Alternatively, it could be that NOTCH1 and NOTCH3 are hyperacetylated 
following treatment with TSA and this might increase their turnover. These 
hypothesis, if confirmed, would indicate that the mechanism of action is more 
related to transcription factor rather than global hyperacetylation, as recently 
found in some experimental models (Christensen et al., 2014). With regard to 
NOTCH receptors and HDACi, Palermo et al. recently demonstrated down-
regulation of NOTCH3 active ICD domain by TSA in MOLT3 cell line and in 
NOTCH3 transgenic mice (Palermo et al., 2012). In this paper, NOTCH3 ICD 
acetylation is unbalanced by HDAC inhibition, leading to increased ubiquitination 
and proteasome-dependent degradation. Our results on HDCAi-dependent 
NOTCH3 full length degradation by the lysosome add a novel mechanism of 
NOTCH3 full-length regulation. Furthermore, in our experiments the proteasome 
inhibitor MG132 further decreased NOTCH3 full-length protein levels. It will be 
interesting to test apoptosis following treatment with HDACi in combination with 
MG132, considering their additive negative effect on NOTCH3 levels. In this 
regard, previous papers reported synergistic effects of proteasome inhibitor 
Bortezomib and HDACi in haematological malignancies such as B-cell precursor 
ALL and CLL  in vitro (Bastian et al., 2013; Dai et al., 2008). 
 
To reinforce these findings we tested Givinostat (ITF 2357), a pan-HDACi now in 
clinical trials. Induction of apoptosis and inhibition of proliferation upon 
Givinostat treatment in vitro were comparable to TSA and, once again, similar 
levels of apoptosis were detected among the different xenografts. Moreover, 
Givinostat showed similar effects on transcription factors as TSA. Interestingly, 
we found that p16INK - a well-known regulator of the cell cycle (Romagosa et al., 
2011) - was strongly up-regulated after Givinostat treatment. This result is in 
accordance with previous studies linking HDACi activity to changes in the 
expression of cell cycle regulatory genes (Fandy et al., 2005; Siavoshian et al., 
2000) and is consistent with the anti-proliferative effect induced by HDACi in our 
in vitro studies. This finding also shows that the decrease in protein levels of 
various transcription factors was not due to a generalized negative effect on gene 
expression, as HDACi treatment clearly up-regulated the protein levels of this cell 
cycle inhibitor.  
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Supported by these in vitro results, we investigated the in vivo activity of 
Givinostat in a T-ALL mouse model developed in our laboratory. This systemic 
model of T-ALL reproduces the natural history of this tumour and it is an useful 
tool to test the therapeutic activity of new drugs. We adopted short-term and long-
term treatments to analyse the biochemical and therapeutic effects of Givinostat, 
respectively.  
Analysis of TLX-related target genes revealed up-modulation of ALDH1A1, 
GBP5, CCR7 in vivo following Givinostat administration. The modulation of 
these target genes at an early time point from drug administration suggests that 
Givinostat blocks HDACs activity in the TLX-repressor complex. We also 
detected modulation of STAT5A and BIM1, two TAL1 and c-MYB target genes, 
respectively, although these effects were not shared by all the xenografts tested. 
On the contrary, NOTCH target genes remained invariably stable upon Givinostat 
treatment. Since NOTCH receptors are hypothetically down-regulated by HDACi 
through post-transcriptional mechanisms, it is possible that the relatively short 
time from drug administration to sacrifice of the mice (6 h) was not sufficient to 
reduce expression of NOTCH target genes.  
Finally, we asked whether primary leukaemias belonging to different T-ALL 
subgroups could respond differentially to long term treatment with Givinostat in 
vivo. In our experiments, TLX-driven xenografts including PD-TALL8 (TLX1) 
and PD-TALL16 (TLX3) were the best responders to Givinostat. Anti-tumour 
effects were predominant in the spleen compared with the bone marrow, perhaps 
due to some features of the BM microenvironment, such as hypoxia, which may 
protect T-ALL cells from drug-induced apoptosis. The TAL-LMO xenografts 
(PD-TALL12 and PD-TALL9) had minor therapeutic responses to Givinostat.  
Since TLX1/TLX3 are transcriptional repressors of differentiation through a 
molecular complex involving also HDAC (Dadi et al., 2012; Sun et al., 2007), 
ongoing experiments are aimed at investigating whether Givinostat may primarily 
act by restoring cell differentiation. 
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Fig. 24: Putative mechanism of action of HDACi in TLX-driven T-ALL xenografts. In normal 
conditions, TLX1/3 recruit HDACs and form a silencing complex on target genes promoter, 
leading to transcriptional repression (top). Upon HDACi treatment, HDACs activity is impaired 
and histones are hyperacetylated. Chromatin expansion is associated with increased expression of 
TLX target genes that induce differentiation of T-ALL cells. 
 
 
 
 
 
 
 
 
 
 
 68 
6. REFERENCES 
Aifantis, I., Raetz, E., and Buonamici, S. (2008). Molecular pathogenesis of T-cell 
leukaemia and lymphoma. Nat Rev Immunol 8, 380-390. 
 
Aldana-Masangkay, G. I., Rodriguez-Gonzalez, A., Lin, T., Ikeda, A. K., Hsieh, 
Y. T., Kim, Y. M., Lomenick, B., Okemoto, K., Landaw, E. M., Wang, D., et al. 
(2011). Tubacin suppresses proliferation and induces apoptosis of acute 
lymphoblastic leukemia cells. Leuk Lymphoma 52, 1544-1555. 
 
Bastian, L., Hof, J., Pfau, M., Fichtner, I., Eckert, C., Henze, G., Prada, J., von 
Stackelberg, A., Seeger, K., and Shalapour, S. (2013). Synergistic activity of 
bortezomib and HDACi in preclinical models of B-cell precursor acute 
lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-kappaB. Clin 
Cancer Res 19, 1445-1457. 
 
Bellavia, D., Campese, A. F., Alesse, E., Vacca, A., Felli, M. P., Balestri, A., 
Stoppacciaro, A., Tiveron, C., Tatangelo, L., Giovarelli, M., et al. (2000). 
Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 
transgenic mice. EMBO J 19, 3337-3348. 
 
Blumenschein, G. R., Jr., Kies, M. S., Papadimitrakopoulou, V. A., Lu, C., 
Kumar, A. J., Ricker, J. L., Chiao, J. H., Chen, C., and Frankel, S. R. (2008). 
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, 
suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or 
metastatic head and neck cancer. Invest New Drugs 26, 81-87. 
 
Boissinot, M., Inman, M., Hempshall, A., James, S. R., Gill, J. H., Selby, P., 
Bowen, D. T., Grigg, R., and Cockerill, P. N. (2012). Induction of differentiation 
and apoptosis in leukaemic cell lines by the novel benzamide family histone 
deacetylase 2 and 3 inhibitor MI-192. Leuk Res 36, 1304-1310. 
 
Bolden, J. E., Peart, M. J., and Johnstone, R. W. (2006). Anticancer activities of 
histone deacetylase inhibitors. Nat Rev Drug Discov 5, 769-784. 
 
Boyault, C., Zhang, Y., Fritah, S., Caron, C., Gilquin, B., Kwon, S. H., Garrido, 
C., Yao, T. P., Vourc'h, C., Matthias, P., and Khochbin, S. (2007). HDAC6 
controls major cell response pathways to cytotoxic accumulation of protein 
aggregates. Genes Dev 21, 2172-2181. 
 
Campana, D., and Coustan-Smith, E. (2012). Measurements of treatment response 
in childhood acute leukemia. Korean J Hematol 47, 245-254. 
 
Cardoso, B. A., de Almeida, S. F., Laranjeira, A. B., Carmo-Fonseca, M., Yunes, 
J. A., Coffer, P. J., and Barata, J. T. (2011). TAL1/SCL is downregulated upon 
histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells. 
Leukemia 25, 1578-1586. 
 
 69 
Chambers, A. E., Banerjee, S., Chaplin, T., Dunne, J., Debernardi, S., Joel, S. P., 
and Young, B. D. (2003). Histone acetylation-mediated regulation of genes in 
leukaemic cells. Eur J Cancer 39, 1165-1175. 
 
Choi, J. H., Kwon, H. J., Yoon, B. I., Kim, J. H., Han, S. U., Joo, H. J., and Kim, 
D. Y. (2001). Expression profile of histone deacetylase 1 in gastric cancer tissues. 
Jpn J Cancer Res 92, 1300-1304. 
 
Christensen, D. P., Gysemans, C., Lundh, M., Dahllof, M. S., Noesgaard, D., 
Schmidt, S. F., Mandrup, S., Birkbak, N., Workman, C. T., Piemonti, L., et al. 
(2014). Lysine deacetylase inhibition prevents diabetes by chromatin-independent 
immunoregulation and beta-cell protection. Proc Natl Acad Sci U S A 111, 1055-
1059. 
 
Clague, M. J., and Urbe, S. (2010). Ubiquitin: same molecule, different 
degradation pathways. Cell 143, 682-685. 
 
Clappier, E., Cuccuini, W., Kalota, A., Crinquette, A., Cayuela, J. M., Dik, W. A., 
Langerak, A. W., Montpellier, B., Nadel, B., Walrafen, P., et al. (2007). The C-
MYB locus is involved in chromosomal translocation and genomic duplications in 
human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL 
subtype in very young children. Blood 110, 1251-1261. 
 
Dadi, S., Le Noir, S., Payet-Bornet, D., Lhermitte, L., Zacarias-Cabeza, J., 
Bergeron, J., Villarese, P., Vachez, E., Dik, W. A., Millien, C., et al. (2012). TLX 
homeodomain oncogenes mediate T cell maturation arrest in T-ALL via 
interaction with ETS1 and suppression of TCRalpha gene expression. Cancer Cell 
21, 563-576. 
 
Dai, Y., Chen, S., Kramer, L. B., Funk, V. L., Dent, P., and Grant, S. (2008). 
Interactions between bortezomib and romidepsin and belinostat in chronic 
lymphocytic leukemia cells. Clin Cancer Res 14, 549-558. 
 
de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S., and van Kuilenburg, 
A. B. (2003). Histone deacetylases (HDACs): characterization of the classical 
HDAC family. Biochem J 370, 737-749. 
 
Della Gatta, G., Palomero, T., Perez-Garcia, A., Ambesi-Impiombato, A., Bansal, 
M., Carpenter, Z. W., De Keersmaecker, K., Sole, X., Xu, L., Paietta, E., et al. 
(2012). Reverse engineering of TLX oncogenic transcriptional networks identifies 
RUNX1 as tumor suppressor in T-ALL. Nat Med 18, 436-440. 
 
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., 
Reilly, J. F., Ricker, J. L., Richon, V. M., and Frankel, S. R. (2007). Phase 2 trial 
of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory 
cutaneous T-cell lymphoma (CTCL). Blood 109, 31-39. 
 
Fandy, T. E., Shankar, S., Ross, D. D., Sausville, E., and Srivastava, R. K. (2005). 
Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated 
with changes in mitochondrial functions and expressions of cell cycle regulatory 
genes in multiple myeloma. Neoplasia 7, 646-657. 
 70 
 
Ferrando, A. A., Neuberg, D. S., Staunton, J., Loh, M. L., Huard, C., Raimondi, S. 
C., Behm, F. G., Pui, C. H., Downing, J. R., Gilliland, D. G., et al. (2002). Gene 
expression signatures define novel oncogenic pathways in T cell acute 
lymphoblastic leukemia. Cancer Cell 1, 75-87. 
 
Gao, Y. S., Hubbert, C. C., and Yao, T. P. (2010). The microtubule-associated 
histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor 
(EGFR) endocytic trafficking and degradation. J Biol Chem 285, 11219-11226. 
 
Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, 
W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., et al. (2008). Phase 1 study 
of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid 
[SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. 
Blood 111, 1060-1066. 
 
Glaser, K. B., Staver, M. J., Waring, J. F., Stender, J., Ulrich, R. G., and 
Davidsen, S. K. (2003). Gene expression profiling of multiple histone deacetylase 
(HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in 
T24 and MDA carcinoma cell lines. Mol Cancer Ther 2, 151-163. 
 
Gojo, I., Jiemjit, A., Trepel, J. B., Sparreboom, A., Figg, W. D., Rollins, S., 
Tidwell, M. L., Greer, J., Chung, E. J., Lee, M. J., et al. (2007). Phase 1 and 
pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with 
refractory and relapsed acute leukemias. Blood 109, 2781-2790. 
 
Graux, C., Cools, J., Michaux, L., Vandenberghe, P., and Hagemeijer, A. (2006). 
Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: 
from thymocyte to lymphoblast. Leukemia 20, 1496-1510. 
 
Gregoretti, I. V., Lee, Y. M., and Goodson, H. V. (2004). Molecular evolution of 
the histone deacetylase family: functional implications of phylogenetic analysis. J 
Mol Biol 338, 17-31. 
 
Groselj, B., Sharma, N. L., Hamdy, F. C., Kerr, M., and Kiltie, A. E. (2013). 
Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage 
signalling and repair. Br J Cancer 108, 748-754. 
 
Gruhn, B., Naumann, T., Gruner, D., Walther, M., Wittig, S., Becker, S., Beck, J. 
F., and Sonnemann, J. (2013). The expression of histone deacetylase 4 is 
associated with prednisone poor-response in childhood acute lymphoblastic 
leukemia. Leuk Res 37, 1200-1207. 
 
Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., and Robson, C. 
N. (2004). Upregulation and nuclear recruitment of HDAC1 in hormone 
refractory prostate cancer. Prostate 59, 177-189. 
 
Inaba, H., and Pui, C. H. (2010). Glucocorticoid use in acute lymphoblastic 
leukaemia. Lancet Oncol 11, 1096-1106. 
 
 71 
Johnstone, R. W., and Licht, J. D. (2003). Histone deacetylase inhibitors in cancer 
therapy: is transcription the primary target? Cancer Cell 4, 13-18. 
 
Kirschbaum, M., Frankel, P., Popplewell, L., Zain, J., Delioukina, M., Pullarkat, 
V., Matsuoka, D., Pulone, B., Rotter, A. J., Espinoza-Delgado, I., et al. (2011). 
Phase II study of vorinostat for treatment of relapsed or refractory indolent non-
Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 29, 1198-1203. 
 
Lahortiga, I., De Keersmaecker, K., Van Vlierberghe, P., Graux, C., Cauwelier, 
B., Lambert, F., Mentens, N., Beverloo, H. B., Pieters, R., Speleman, F., et al. 
(2007). Duplication of the MYB oncogene in T cell acute lymphoblastic 
leukemia. Nat Genet 39, 593-595. 
 
Lewis, H. D., Leveridge, M., Strack, P. R., Haldon, C. D., O'Neil, J., Kim, H., 
Madin, A., Hannam, J. C., Look, A. T., Kohl, N., et al. (2007). Apoptosis in T cell 
acute lymphoblastic leukemia cells after cell cycle arrest induced by 
pharmacological inhibition of notch signaling. Chem Biol 14, 209-219. 
 
Lin, R. J., Sternsdorf, T., Tini, M., and Evans, R. M. (2001). Transcriptional 
regulation in acute promyelocytic leukemia. Oncogene 20, 7204-7215. 
 
Liu, L. T., Chang, H. C., Chiang, L. C., and Hung, W. C. (2003). Histone 
deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer 
cell invasion. Cancer Res 63, 3069-3072. 
 
Lorenzo, P. I., Brendeford, E. M., Gilfillan, S., Gavrilov, A. A., Leedsak, M., 
Razin, S. V., Eskeland, R., Saether, T., and Gabrielsen, O. S. (2011). 
Identification of c-Myb Target Genes in K562 Cells Reveals a Role for c-Myb as 
a Master Regulator. Genes Cancer 2, 805-817. 
 
Ma, X., Ezzeldin, H. H., and Diasio, R. B. (2009). Histone deacetylase inhibitors: 
current status and overview of recent clinical trials. Drugs 69, 1911-1934. 
 
Marks, P. A. (2010). Histone deacetylase inhibitors: a chemical genetics approach 
to understanding cellular functions. Biochim Biophys Acta 1799, 717-725. 
 
Meijerink, J. P. (2010). Genetic rearrangements in relation to immunophenotype 
and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin 
Haematol 23, 307-318. 
 
Minucci, S., and Pelicci, P. G. (2006). Histone deacetylase inhibitors and the 
promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6, 38-51. 
 
Moreno, D. A., Scrideli, C. A., Cortez, M. A., de Paula Queiroz, R., Valera, E. T., 
da Silva Silveira, V., Yunes, J. A., Brandalise, S. R., and Tone, L. G. (2010). 
Differential expression of HDAC3, HDAC7 and HDAC9 is associated with 
prognosis and survival in childhood acute lymphoblastic leukaemia. Br J 
Haematol 150, 665-673. 
 
 72 
Nolan, L., Johnson, P. W., Ganesan, A., Packham, G., and Crabb, S. J. (2008). 
Will histone deacetylase inhibitors require combination with other agents to fulfil 
their therapeutic potential? Br J Cancer 99, 689-694. 
 
O'Neil, J., Shank, J., Cusson, N., Murre, C., and Kelliher, M. (2004). TAL1/SCL 
induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer 
Cell 5, 587-596. 
 
Palermo, R., Checquolo, S., Giovenco, A., Grazioli, P., Kumar, V., Campese, A. 
F., Giorgi, A., Napolitano, M., Canettieri, G., Ferrara, G., et al. (2012). 
Acetylation controls Notch3 stability and function in T-cell leukemia. Oncogene 
31, 3807-3817. 
 
Palomero, T., Lim, W. K., Odom, D. T., Sulis, M. L., Real, P. J., Margolin, A., 
Barnes, K. C., O'Neil, J., Neuberg, D., Weng, A. P., et al. (2006). NOTCH1 
directly regulates c-MYC and activates a feed-forward-loop transcriptional 
network promoting leukemic cell growth. Proc Natl Acad Sci U S A 103, 18261-
18266. 
 
Pan, L. N., Lu, J., and Huang, B. (2007). HDAC inhibitors: a potential new 
category of anti-tumor agents. Cell Mol Immunol 4, 337-343. 
 
Pui, C. H. (2009). Acute lymphoblastic leukemia: introduction. Semin Hematol 
46, 1-2. 
 
Pui, C. H., and Evans, W. E. (2006). Treatment of acute lymphoblastic leukemia. 
N Engl J Med 354, 166-178. 
 
Rakowski, L. A., Lehotzky, E. A., and Chiang, M. Y. (2011). Transient responses 
to NOTCH and TLX1/HOX11 inhibition in T-cell acute lymphoblastic 
leukemia/lymphoma. PLoS One 6, e16761. 
 
Reed, N. A., Cai, D., Blasius, T. L., Jih, G. T., Meyhofer, E., Gaertig, J., and 
Verhey, K. J. (2006). Microtubule acetylation promotes kinesin-1 binding and 
transport. Curr Biol 16, 2166-2172. 
 
Rice, K. L., Izon, D. J., Ford, J., Boodhoo, A., Kees, U. R., and Greene, W. K. 
(2008). Overexpression of stem cell associated ALDH1A1, a target of the 
leukemogenic transcription factor TLX1/HOX11, inhibits lymphopoiesis and 
promotes myelopoiesis in murine hematopoietic progenitors. Leuk Res 32, 873-
883. 
 
Rodriguez-Gonzalez, A., Lin, T., Ikeda, A. K., Simms-Waldrip, T., Fu, C., and 
Sakamoto, K. M. (2008). Role of the aggresome pathway in cancer: targeting 
histone deacetylase 6-dependent protein degradation. Cancer Res 68, 2557-2560. 
 
Romagosa, C., Simonetti, S., Lopez-Vicente, L., Mazo, A., Lleonart, M. E., 
Castellvi, J., and Ramon y Cajal, S. (2011). p16(Ink4a) overexpression in cancer: 
a tumor suppressor gene associated with senescence and high-grade tumors. 
Oncogene 30, 2087-2097. 
 
 73 
Rosato, R. R., Almenara, J. A., Dai, Y., and Grant, S. (2003). Simultaneous 
activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) 
inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 
synergistically induces mitochondrial damage and apoptosis in human leukemia 
cells. Mol Cancer Ther 2, 1273-1284. 
 
Ross, M. E., Zhou, X., Song, G., Shurtleff, S. A., Girtman, K., Williams, W. K., 
Liu, H. C., Mahfouz, R., Raimondi, S. C., Lenny, N., et al. (2003). Classification 
of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 
102, 2951-2959. 
 
Ruefli, A. A., Ausserlechner, M. J., Bernhard, D., Sutton, V. R., Tainton, K. M., 
Kofler, R., Smyth, M. J., and Johnstone, R. W. (2001). The histone deacetylase 
inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) 
induces a cell-death pathway characterized by cleavage of Bid and production of 
reactive oxygen species. Proc Natl Acad Sci U S A 98, 10833-10838. 
 
Ryningen, A., Stapnes, C., and Bruserud, O. (2007). Clonogenic acute 
myelogenous leukemia cells are heterogeneous with regard to regulation of 
differentiation and effect of epigenetic pharmacological targeting. Leuk Res 31, 
1303-1313. 
 
Sanda, T., Lawton, L. N., Barrasa, M. I., Fan, Z. P., Kohlhammer, H., Gutierrez, 
A., Ma, W., Tatarek, J., Ahn, Y., Kelliher, M. A., et al. (2012). Core 
transcriptional regulatory circuit controlled by the TAL1 complex in human T cell 
acute lymphoblastic leukemia. Cancer Cell 22, 209-221. 
 
Sandor, V., Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., 
Blagosklonny, M. V., and Bates, S. E. (2000). P21-dependent g(1)arrest with 
downregulation of cyclin D1 and upregulation of cyclin E by the histone 
deacetylase inhibitor FR901228. Br J Cancer 83, 817-825. 
 
Sarvaiya, P. J., Schwartz, J. R., Hernandez, C. P., Rodriguez, P. C., and Vedeckis, 
W. V. (2012). Role of c-Myb in the survival of pre B-cell acute lymphoblastic 
leukemia and leukemogenesis. Am J Hematol 87, 969-976. 
 
Sasakawa, Y., Naoe, Y., Noto, T., Inoue, T., Sasakawa, T., Matsuo, M., Manda, 
T., and Mutoh, S. (2003). Antitumor efficacy of FK228, a novel histone 
deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. 
Biochem Pharmacol 66, 897-906. 
 
Screpanti, I., Bellavia, D., Campese, A. F., Frati, L., and Gulino, A. (2003). 
Notch, a unifying target in T-cell acute lymphoblastic leukemia? Trends Mol Med 
9, 30-35. 
 
Siavoshian, S., Segain, J. P., Kornprobst, M., Bonnet, C., Cherbut, C., Galmiche, 
J. P., and Blottiere, H. M. (2000). Butyrate and trichostatin A effects on the 
proliferation/differentiation of human intestinal epithelial cells: induction of 
cyclin D3 and p21 expression. Gut 46, 507-514. 
 
 74 
Song, J., Noh, J. H., Lee, J. H., Eun, J. W., Ahn, Y. M., Kim, S. Y., Lee, S. H., 
Park, W. S., Yoo, N. J., Lee, J. Y., and Nam, S. W. (2005). Increased expression 
of histone deacetylase 2 is found in human gastric cancer. APMIS 113, 264-268. 
 
Soulier, J., Clappier, E., Cayuela, J. M., Regnault, A., Garcia-Peydro, M., 
Dombret, H., Baruchel, A., Toribio, M. L., and Sigaux, F. (2005). HOXA genes 
are included in genetic and biologic networks defining human acute T-cell 
leukemia (T-ALL). Blood 106, 274-286. 
 
Stenman, G., Andersson, M. K., and Andren, Y. (2010). New tricks from an old 
oncogene: gene fusion and copy number alterations of MYB in human cancer. 
Cell Cycle 9, 2986-2995. 
 
Sulis, M. L., Williams, O., Palomero, T., Tosello, V., Pallikuppam, S., Real, P. J., 
Barnes, K., Zuurbier, L., Meijerink, J. P., and Ferrando, A. A. (2008). NOTCH1 
extracellular juxtamembrane expansion mutations in T-ALL. Blood 112, 733-740. 
 
Sun, G., Yu, R. T., Evans, R. M., and Shi, Y. (2007). Orphan nuclear receptor 
TLX recruits histone deacetylases to repress transcription and regulate neural stem 
cell proliferation. Proc Natl Acad Sci U S A 104, 15282-15287. 
 
Thiagalingam, S., Cheng, K. H., Lee, H. J., Mineva, N., Thiagalingam, A., and 
Ponte, J. F. (2003). Histone deacetylases: unique players in shaping the epigenetic 
histone code. Ann N Y Acad Sci 983, 84-100. 
 
Thompson, B. J., Buonamici, S., Sulis, M. L., Palomero, T., Vilimas, T., Basso, 
G., Ferrando, A., and Aifantis, I. (2007). The SCFFBW7 ubiquitin ligase complex 
as a tumor suppressor in T cell leukemia. J Exp Med 204, 1825-1835. 
 
Tosello, V., and Ferrando, A. A. (2013). The NOTCH signaling pathway: role in 
the pathogenesis of T-cell acute lymphoblastic leukemia and implication for 
therapy. Ther Adv Hematol 4, 199-210. 
 
Ungerstedt, J. S., Sowa, Y., Xu, W. S., Shao, Y., Dokmanovic, M., Perez, G., 
Ngo, L., Holmgren, A., Jiang, X., and Marks, P. A. (2005). Role of thioredoxin in 
the response of normal and transformed cells to histone deacetylase inhibitors. 
Proc Natl Acad Sci U S A 102, 673-678. 
 
Vansteenkiste, J., Van Cutsem, E., Dumez, H., Chen, C., Ricker, J. L., Randolph, 
S. S., and Schoffski, P. (2008). Early phase II trial of oral vorinostat in relapsed or 
refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 26, 
483-488. 
 
Ververis, K., Hiong, A., Karagiannis, T. C., and Licciardi, P. V. (2013). Histone 
deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7, 
47-60. 
 
Vilas-Zornoza, A., Agirre, X., Abizanda, G., Moreno, C., Segura, V., De Martino 
Rodriguez, A., Jose-Eneriz, E. S., Miranda, E., Martin-Subero, J. I., Garate, L., et 
al. (2012). Preclinical activity of LBH589 alone or in combination with 
 75 
chemotherapy in a xenogeneic mouse model of human acute lymphoblastic 
leukemia. Leukemia 26, 1517-1526. 
 
Waldron, T., De Dominici, M., Soliera, A. R., Audia, A., Iacobucci, I., Lonetti, 
A., Martinelli, G., Zhang, Y., Martinez, R., Hyslop, T., et al. (2012). c-Myb and 
its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and 
human cells. Leukemia 26, 644-653. 
 
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P. t., Silverman, L. B., Sanchez-
Irizarry, C., Blacklow, S. C., Look, A. T., and Aster, J. C. (2004). Activating 
mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 
306, 269-271. 
 
Wilson, A. J., Byun, D. S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., 
Arango, D., Velcich, A., Augenlicht, L. H., and Mariadason, J. M. (2006). Histone 
deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation 
and p21 expression and are deregulated in human colon cancer. J Biol Chem 281, 
13548-13558. 
 
Xu, W. S., Parmigiani, R. B., and Marks, P. A. (2007). Histone deacetylase 
inhibitors: molecular mechanisms of action. Oncogene 26, 5541-5552. 
 
Yeoh, E. J., Ross, M. E., Shurtleff, S. A., Williams, W. K., Patel, D., Mahfouz, R., 
Behm, F. G., Raimondi, S. C., Relling, M. V., Patel, A., et al. (2002). 
Classification, subtype discovery, and prediction of outcome in pediatric acute 
lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133-143. 
 
Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., and Matthias, 
P. (2003). HDAC-6 interacts with and deacetylates tubulin and microtubules in 
vivo. EMBO J 22, 1168-1179. 
 
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., Mita, K., 
Hamaguchi, M., Hara, Y., Kobayashi, S., and Iwase, H. (2005). Quantitation of 
HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer 
Res Treat 94, 11-16. 
 
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Omoto, Y., Ando, Y., Mita, 
K., Hamaguchi, M., Hayashi, S., and Iwase, H. (2004). HDAC6 expression is 
correlated with better survival in breast cancer. Clin Cancer Res 10, 6962-6968. 
 
Zhou, F., Zhang, L., van Laar, T., van Dam, H., and Ten Dijke, P. (2011). 
GSK3beta inactivation induces apoptosis of leukemia cells by repressing the 
function of c-Myb. Mol Biol Cell 22, 3533-3540. 
 
Zhu, P., Martin, E., Mengwasser, J., Schlag, P., Janssen, K. P., and Gottlicher, M. 
(2004). Induction of HDAC2 expression upon loss of APC in colorectal 
tumorigenesis. Cancer Cell 5, 455-463. 
 
 
 
